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EDITORIAL
It is our pleasure to bring you the "Infection and
Immunity" issue of the UWOMJ. Today,
infection remains an issue of great concern. While
cancer is the leading cause of death in North
America, infectious disease causes the greatest
number of deaths globally.
To highlight this significant topic, this
edition of the UWOMJ incorporates a wide range
of fascinating articles. Furthermore, exciting
structural developments have taken place within
the journal itself, including the addition of a brand
new departmental section: Interdisciplinary
Collaboration. This focus reflects the growing
multidisciplinary nature of health care today. In
addition, original research and case reports make
their debut in the following pages. More so than
ever before, our departmental editors and writers
have collaborated in producing this impressive
edition.
We are proud that this unique edition
brings attention to an extremely rare case of
genitourinary tuberculosis, as well as the first
reported case of ictal asystole secondary to an
infection with herpes simplex virus. Our authors
present an interesting perspective on the history
of a well-established infection commonly known
as fifth disease.
Not only are rare and curious cases and
medical history included, but an up-to-date
discussion of the world's major health concerns,
including avian influenza, tuberculosis, rabies,
and listeriosis round out our article collection. We
now focus on prevention on a much larger scale,
on an international rather than on a local basis.
For instance, the possibility of an avian influenza
pandemic
has
changed
our
worldwide
perspective. Major strides in combating infections
have been made with the advent of vaccines; a
number of our articles look at the factors
surrounding these breakthroughs.
Have
you
wondered
what
the
environmental impact and infectious risk of your
UWO Medical Journal, Vol 78, Issue 2

daily actions entail? Significant community health
concerns are addressed in an intriguing article
demystifying infection prevention.
Furthermore, infection is a social and
anthropological concern. Poverty, poor access to
health care, and lack of education are just a few of
the many determinants of health. Such social
factors are eloquently highlighted in a feature
article focusing on the burden of respiratory
infections in homeless populations.
For a far more personal viewpoint, an
intimate career interview with Dr. Marina
Salvadori, a pediatric infectious disease specialist,
will inspire future doctors. Her career path
demonstrates that a genuine passion for medicine
can translate to advocacy work, global health and
tangible
effects
on
health
policy.
Attractively binding this vast array of
articles together, our cover art addresses the most
pressing infectious health concern of our age –
HIV – in both a stylistic and unique manner. The
inside cover art is another testament to the
genuine aesthetic talent and skill of medical
students today. The creative geniuses of our
artistic colleagues deliver the essence of infection
and immunity, organized in a professional format
designed by our new layout editor.
Overall, the cutting edge pieces included
in this issue are a tribute to the hard work and
research talent of our contributors, authors and
editors. As always, the collective efforts of
University of Western Ontario medical students
are manifested in this impressive edition of the
UWOMJ.
Special thanks go out to our managing
editorial team for their drive and dedication in
bringing this issue together. We would also like to
express our appreciation for the many faculty
reviewers who have contributed to the high
quality of the articles published herein. Enjoy!
- Wendy Ng and Amber Menezes
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CLINICAL PROCEDURES
Procedural approaches to drainage of prostatic abscesses
Paul Lau (Meds 2011) and Edward Weiss (Meds 2012)
Faculty Reviewer: Dr. Hassan Razvi, Department of Surgery, Division of Urology
Prostatic abscesses are a rare complication of acute prostatitis, and an uncommon clinical entity in the
antibiotic era. Despite their rarity, untreated abscesses still remain potentially life-threatening, and require
formal drainage to permit resolution. The transurethral approach to drainage used in the past has more
recently given way to percutaneous interventions aided by trans-rectal ultrasonography. Although none of
the currently-used strategies have proven ideal for complex cases, improved imaging techniques are
expected to further increase the efficacy of percutaneous interventions and establish them as the standard of
practice for treating prostatic abscesses.
Introduction
Prostatic abscesses (PAs) are defined by the
accumulation of purulent material in one or more
focal areas of the prostate. With the advent of
antibiotic therapy in the twentieth century, PA has
become a rare clinical entity. However, it can still
present as a complication of acute bacterial
prostatitis, which itself is thought to be caused by
intraprostatic urinary reflux, ascending urethral
infection, or hematogenous spread from an
infection elsewhere in the body. Left untreated,
PAs can rupture and progress to sepsis, as well as
fistulization of the bladder, urethra, and rectum.1
Thus, the need for expeditious diagnosis and
treatment is not to be underestimated.
Symptoms of PA often mimic those of
acute bacterial prostatitis (ABP) – fever, dysuria,
low back and perineal discomfort, and pain upon
palpation of the prostate. In the course of a digital
rectal exam, the abscessed prostate is usually
discovered to be enlarged, and sometimes
fluctuant. The use of transrectal ultrasound or
other imaging modalities such as computed
tomography (CT) can provide radiological
confirmation of the abscess even in the absence of
prostatic fluctuation. On occasion the condition is
suspected when the patient fails to respond to
appropriately selected antimicrobial coverage.

UWO Medical Journal, Vol 78, Issue 2

Before the introduction of inexpensive and
readily-available antibiotics, prostatic abscesses
were often seen in sexually active young men as a
result of infection with Neisseria gonorrhoeae.
Because of the lack of diagnostic and
interventional strategies, many patients presented
with systemic infection due to spontaneous
rupture of the abscess into nearby structures and
cavities, and mortality has been estimated to have
been as high as 30%.2 More recently, the advent
of antibiotic therapy has seen a marked decrease
in the morbidity and mortality associated with
PA, as well as concomitant changes in
bacteriology and epidemiology. The most
common organisms now encountered include
Escherichia coli and Staphylococcus aureus,1,3
and the disease is classically found in older men
with predisposing factors such as diabetes,
ongoing dialysis, or a history of urethral
catheterization.1
The microbiological profile of PAs has
also shifted in the wake of the increasing
prevalence of immunodeficiency. Patients with
AIDS have been known to present with abscesses
caused by Mycobacterium tuberculosis,4 and in
other settings of immunodeficiency, such as
immunosuppression
following
organ
transplantation, organisms cultured from PAs
have included Cryptococcus,5 Aspergillus,6 and
Candida.7 There is also preliminary evidence
indicating that the increasing prevalence of
Page | 5

diabetes in some regions is associated with a
higher incidence of PA in younger men,3 which
may reflect a significant ongoing epidemiological
change that may be significant in the future.
Variable treatment modalities exist for the
drainage of PAs. Transurethral unroofing,
transrectal needle aspiration or transperineal
needle aspiration are all options currently being
used. This article will discuss the indications and
methods for each therapeutic approach, as well as
their respective risks and benefits.
Transurethral approach
prostatic abscess

to

drainage

of

Previously employed by urologists as the standard
approach, the transurethral technique to drainage
of a PA (otherwise known as unroofing) has
recently been replaced by percutaneous
measures.7 However, transurethral unroofing of
PAs is still employed for persistent abscesses that
recur despite minimally-invasive treatment.

Figure 1. Transurethral radical prostatectomy is
performed with a resectoscope equipped with a
diathermy loop. The instrument is passed down the
length of the urethra and the resection is performed
with constant irrigation.

The procedure is typically performed
under general anaesthesia with the patient in the
lithotomy position (Figure 1). An electrosurgical
resectoscope armed with either a Colling’s knife
or resectoscope loop is utilized to unroof the PAs
which often are visibly apparent as a bulging
Page | 6

mass.8 Transurethral approaches to drainage of
PAs carry a risk of widespread bacteremia as well
as all complications related to general
anaesthesia.7 Patients may also experience
retrograde ejaculation and rarely urethral stricture
and sphincter dysfunction following the
procedure.9 Additionally, transurethral unroofing
is ineffective in patients presenting with
peripherally located abscesses and multiloculated
abscesses. The location and complexity of these
abscesses leads to incomplete drainage through
the transurethral approach,10 a complication that
can prove detrimental in immunocompromised
patients. One case report has recommended the
usage of sonographic guidance in conjunction
with transurethral unroofing to treat complex
abscesses; however, this has not been validated by
further studies.
Transrectal approach to drainage of prostatic
abscess
The first of two percutaneous methods to drain
PAs, the transrectal approach utilizes a transrectal
ultrasound (TRUS) to guide a needle through the
rectal wall and into the PA for drainage (Figure
2). The procedure is performed under local
anaesthesia with the patient in the left lateral
decubitus position.11 Lavage following drainage
allows for antibiotics to be introduced directly
into the post-drainage cavity.
In contrast to transurethral unroofing, the
transrectal approach can be utilized for complex
abscesses as TRUS enables direct visualization of
the abscess and minimal tissue manipulation
reducing the morbidity of the procedure. This
technique requires no general anaesthetic and is
less painful then the transperineal approach.
Despite the advantages of TRUS guided drainage,
Gan et al have demonstrated that repeat
procedures for multiloculated abscesses are
common using this method.12 Formation of rectourethral fistulae and potential prostatic
contamination by rectal bacteria may also
complicate recovery following drainage.

inability of the TRUS to adequately allow for
complete drainage of multiloculated abscesses.
However, the recent utility of 3D TRUS has
shown promising results in the management of
multiloculated abscesses by the transperineal
approach.

Figure 3. Transperineal needle aspiration of
prostatic abscess. The transducer of the transrectal
ultrasound is placed in the rectum (R), and the fine
needle (N) has been guided ultasonographically
into the prostate (P).
Figure 2. A transrectal ultrasound probe with
attached needle is used to puncture the prostate.
NB: This image depicts a probe equipped with a
biopsy gun. For drainage of prostatic abscesses, a
fine needle or catheter is used, often introduced
through an intra-probe needle canal.

Transperineal approach
prostatic abscess

to

drainage

of

Another percutaneous approach to drainage of
PAs, the transperineal approach also employs the
use of TRUS to guide a needle puncturing the
perineum into the prostatic abscess.13 The
procedure is painful and may require the use of
general anaesthesia although most procedures are
tolerable under local anaesthesia. The patient is
placed in the lithotomy position and a needle is
advanced from the perineum into the prostate
(Figure 3). Following complete drainage of the
abscess, a guidewire is placed into the cavity and
dilatation of the puncture tract is achieved via the
Seldinger technique. A loop catheter is then
placed for further drainage and is left in place for
several days.
The transperineal approach is preferred
over the transrectal approach by some clinicians
due to the increased chances of complete drainage
via the loop catheter. Disadvantages of the
transperineal approach are also related to the
UWO Medical Journal, Vol 78, Issue 2

Discussion
In the post antibiotic era, PA is a rare
manifestation of a urinary tract infection.
Regardless, a failure to diagnose and promptly
treat can cause significant morbidity. Current
practices utilize imaging for diagnostic purposes.
Existing data shows that the use of TRUS for the
diagnosis of prostatic abscess is as sensitive as
CT or magnetic resonance imaging.14 With the
ease of use and lack of ionizing radiation, TRUS
is the gold standard for diagnosis and
visualization of a prostatic abscess.13 The
diagnostic criteria include the presence of
hypoechogeneic areas containing thick liquid in
the transition and central zones of the prostate
permeated with hyperechogeneic areas as well as
enlargement or distortion of the anatomy of the
gland. There is also a role for urinary culture for
selection of pre-procedural antibiotics.
Although all three approaches to drainage
of PAs are still being employed, the percutaneous
measures (transrectal and transperineal) have
come into favour due to their less invasive nature
and association with lower morbidity.7 Each
procedure has been shown in literature to have
potential for incomplete drainage although the
recent evidence favouring 3D TRUS showed
Page | 7

complete drainage in all 7 patients studied.13
Regardless of procedure, antibiotics are a key
component in the management strategies of PAs.
Antibiotics should be given orally or
intravenously before any procedure to drain a
PA.8 Once drainage is complete, culture and
sensitivity testing allows for a more targeted
approach towards eradication of the infection.

3.

4.
5.

Conclusion
6.

With the incidence of prostatic abscess at a
historic low, it is likely that many clinicians may
go their entire careers without encountering what
was once a fairly common presentation. However,
the possibility of severe sequelae pursuant to an
untreated PA and the suggestion that its incidence
may rise in the future represent a strong impetus
for becoming acquainted with the diagnostic and
interventional strategies required to treat PA.
Percutaneous transrectal or transperineal needle
aspiration with ultrasonographic guidance have
shown to be effective and minimally invasive
treatment modalities, and future refinement of
current ultrasound technology promises to extend
successful treatment to more complex and
resistant abscesses.

7.
8.
9.

10.

11.
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DIAGNOSTIC REVIEW
Avian influenza: an emerging infectious disease with pandemic
potential
Jason Essue (Meds 2011) and Rachel Bevan (Meds 2012)
Faculty Reviewer: Dr. John McCormick
There are numerous examples of infectious diseases that have wreaked havoc on the human population.
Analysis of previous outbreaks has provided insight into the various ways that infectious diseases can be
transmitted both between members of different species and among members of the same species.
Furthermore, a thorough understanding of past outbreaks enables public health agencies to develop an
informed approach to predict when new emerging or re-emerging infectious diseases will surface.
Anticipating an infectious disease outbreak is essential to preparing an effective response strategy. The
transfer of disease between species is of particular concern as a reservoir of emerging infectious diseases
(EIDs) since approximately 75 percent of EIDs are estimated to have zoonotic origin. Bird-flu, or influenza
strain H5N1, is an emerging disease of avian origin that is expected to cause the next influenza pandemic
and has already begun to surface in humans from a wide geographic area. Frontline clinicians need to be
aware of the signs and symptoms of H5N1 infection. Successful control of an H5N1 outbreak relies upon
accurate identification by clinicians, reporting of an outbreak to public health authorities, and
implementation of infection control procedures in a timely manner. The continued development of new
technological advances that surpass traditional national boundaries, in order to track and report infectious
diseases, is integral for rapid and efficient communication among public health agencies.
Introduction
Throughout history, numerous infectious diseases
have had a large impact upon human health,
through well-known epidemics such as the
bubonic plague, (which most recently broke out in
China in 1855 and is still ongoing) influenza (in
1918 and again in the 1950s), the current HIV
pandemic, and also through the re-emergence of
infectious agents such as Methicillin Resistant
Infectious
Staphylococcus aureus (MRSA).2,3
diseases are estimated by the World Health
Organization
(WHO)
to
have
caused
approximately twenty-five percent of world-wide
deaths in 2002 (15 million people, excluding
complications due to infection as a cause of
death).1 Furthermore, the impact is greatest upon
the disadvantaged and children.1 Influenza
epidemics in particular have demonstrated the
ease with which infectious diseases can spread
throughout the global population,3 and remain a
concern as a re-emerging infectious agent.4
UWO Medical Journal, Vol 78, Issue 2

Emerging Infectious Diseases (EIDs)
EIDs are infectious diseases that have either an
increasing range or incidence.
EIDs are
discovered for various reasons: a previously
unknown disease variant is discovered (e.g.
Helicobacter pylori as a cause for ulcers); a new
agent is created (e.g. Avian Flu is currently an
emerging infectious disease); and the reemergence of a disease after an initial period of
decline (e.g. plague caused by Yersinia pestis is
known to have caused at least 3 known pandemics
which occurred hundreds of years apart).2,3
Factors that precipitate or enhance the spread of
EIDs can be categorized as either those that aid in
the introduction into the host population of the
infectious agent, or those that allow the infectious
agent to become established and spread
throughout the population (Table 1).

Page | 9

Table 1: Factors that promote the introduction and spread of emerging infectious diseases.
Activity
Example
Factors that promote
introduction of EIDs
Factors that promote spread
of EIDs

Economic Development
and Land Use

Exposure to living conditions that allows for zoonotic
transfer (e.g. H5N1)

Microbial Adaptation

Methicillin Resistant S. aureus (MRSA)

International travel &
commerce

Severe Acute Respiratory Syndrome (SARS)

Change/breakdown of
public health measures

Measles and Rubella outbreaks

Technology & Industry

Food poisoning outbreaks

Human
demographics/behaviour

Human Immunodeficiency Virus (HIV)

There are two categories of factors that
promote EIDs: those that promote EID
introduction, and those that promote EID spread.
Note that the activities are taken directly from
Institute of Medicine’s factors for EID.2,3

origins. HIV, which is one of the most prominent
examples of an infectious disease of zoonotic
origins, is thought to have transferred from
simians in Africa through the consumption of
bush meat.4

One analysis of 335 EID events from 1940
to 2004 demonstrated that there has been a
significant increase in EIDs over time, even when
accounting for reporting bias.5 Based upon this
analysis, the majority of EIDs diseases came from
zoonotic events (60.3%), and were caused by
either Rickettsia (gram negative bacteria) and
other bacteria (54.3%).5 Globally, the distribution
is non-random. Indeed, EIDs are most likely to
occur in the lower latitudes, where the fewest
global resources are focused, and reporting is
least common.5
Furthermore, despite the
development of numerous antibiotics and
vaccines, diseases caused by viruses, protozoa,
helminths and fungi are still difficult to treat and
eradicate.2

Bird-flu, or influenza strain H5N1, is a
newly emerging disease of particular public
health concern.3 Influenza is a rapidly mutating
disease with two key surface proteins
(hemagglutinin and neuraminidase) that have a
large effect upon the successful spread and
virulence of the disease. Hemagglutinin is an
influenza surface protein that helps the virus to
bind to cell surface receptors. Key mutations in
hemagglutinin allow the influenza virus to bind
host cells when host immunity has developed
against other hemagglutinin antigens.4 There are
at least 16 known hemagglutinin subtypes.
Neuraminidase is another influenza surface
enzyme that confers virulence to influenza.4 It is a
glycosidic hydrolase enzyme with nine subtypes,
many of which are present only in birds. 4 H5N1
represents an influenza strain that has not
previously infected humans, and contains a
combination of the H5 hemagglutinin and N1
neuraminidase subtypes.3 Currently, H5N1 is
highly virulent in chickens, and has begun to
infect migratory birds. 3 It also has the ability to
jump to humans and other mammals (including
pigs), where it causes a high death toll. 3

Zoonotic origins of EIDs
In general, one of the greatest causes for concern
of newly EIDs is the reservoir found in animals.3,6
Such diseases can transfer to humans either
directly, or through a vector (such as arthropods),
and have the potential to cause epidemics. The
potential for epidemics is especially a cause for
concern if the disease develops the ability to
easily transmit between individuals within a
population.3 Diseases such as HIV and H5N1
(bird-flu) are examples of diseases of zoonotic
Page | 10

H5N1: the next pandemic?
Although H5N1 is largely expected to cause the
next influenza pandemic, the following conditions
must first be met for this to occur: 1) a new
influenza virus subtype must emerge, 2) it must
be capable of infecting humans and causing
serious illness, and 3) it must spread easily from
human to human.7,8 H5N1 is of particular
concern because it has already fulfilled the first
two criteria and more recent reports from the
World Health Organization (WHO) suggest that
partial human-to-human transmission of H5N1
may have occurred in isolated cases in Thailand,
Indonesia, and Vietnam.7,8,9,10
However, at
present, human-to-human transmission has
occurred sporadically and with very low
efficiency and therefore does not meet the third
criteria.7,8,11 Nonetheless, influenza-like viruses
are highly mutagenic11 and may become freely
transmissible among humans at some point in the
future, which means that the threat of an avian
influenza pandemic remains very real.
Based upon past influenza epidemic
outcomes, the United States Congressional
Budget Office (CBO) has projected that a
potential influenza pandemic could involve 200
million people infected, 90 million clinically ill,
and 2 million dead. This would yield a casefatality ratio of 2.5%. Furthermore, the economic
cost could reach $675 billion.12 As of September
2008, the WHO reported that H5N1 has already
infected 387 humans and killed 245 patients
worldwide, with a case-fatality rate of 63%.12
Therefore, the CBO’s projection likely
underestimates the actual impact of an H5N1
pandemic given that the case-fatality ratio of
H5N1 reported by the WHO is 25 times greater
than the estimate put forth by the CBO (63% vs.
2.5%).
Signs of Symptoms of H5N1 Infection
Frontline clinicians need to be aware of the signs
and symptoms of H5N1 infection because
identifying the illness, reporting it to public health
authorities, and implementing infection control
procedures in a timely manner offers the best
chance of controlling the spread of infection.
Symptoms
include
typical
influenza-like
UWO Medical Journal, Vol 78, Issue 2

symptoms: fever greater than 38°C (100%),
cough and sore throat (67%), myalgias (30%),
pneumonia (58%), and diarrhea and vomiting
(50%).7 Symptom onset occurs within 2-14 days
of exposure.11,14 Complications include acute
respiratory
distress
syndrome
(ARDS),
pulmonary hemorrhage, myocarditis, pericarditis,
encephalitis, multi-organ failure with renal
dysfunction, and sepsis.7 Common radiographic
findings include diffuse, multi-focal or patchy
infiltrates and segmental or lobar consolidation
with air bronchograms.7 The majority of the
deaths have been attributed to respiratory failure.7
Diagnosis and Treatment of H5N1
Diagnosing H5N1 infection poses a challenge
because there are no pathognomonic signs and
symptoms making it difficult to distinguish from
other causes of influenza-like illness, severe
community-acquired pneumonia, or ARDS.7,11,14
The only findings that would raise suspicion of
avian influenza (H5N1) is a history of presence in
an endemic area and/or contact with
poultry.7,11,14,15 Therefore, obtaining a detailed
history including travel and animal exposure is
crucial. When H5N1 infection is suspected, the
preferred test to confirm the diagnosis is real-time
reverse transcriptase polymerase chain reaction
(qRT-PCR) on a nasopharyngeal swab.7,11,16
Current opinion of the WHO states that
patients presenting with the symptoms and
historical features that are strongly suggestive of
H5N1 infection should promptly be started on a
course of Oseltamivir, pending the diagnostic
results of PCR testing. 17 Oseltamivir is an
antiviral agent that inhibits neuraminidase, which
has been shown to reduce H5N1 infectionassociated mortality in observational studies when
it is administered in a timely manner.17
Mandatory Reporting of H5N1
Laboratory confirmation of a human case of
H5N1 by qRT-PCR should trigger an immediate
notification of local, sub-national, and national
public health and agricultural authorities.
However, the collection, shipment, and testing of
specimens can often take several days or longer.
Therefore, it is often necessary to notify the
appropriate public health officials and initiate an
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investigation before laboratory test results are
available for persons suspected of having H5N1
infection.18,19 National health authorities must
then notify the WHO and readily share
information and biological specimens.19,20
New methods of surveillance and reporting
EIDs
Although this reporting structure provides a solid
basis in order to approach outbreaks in a globally
concerted manner, the hierarchical nature of the
system could cause unwanted delays in
communication from the local governmental level
to the WHO. Furthermore, some parties may be
less willing to report potential new H5N1
infections for fear of local or national economic
repercussions, leading to further delay.20 For these
reasons, new structures of communication are
being created by public health scientists to share
information more rapidly. ProMED-mail is an email based group dedicated to infectious diseases
with a membership exceeding 30,000, giving the
group global reach and influence.21 ProMED is
known to report outbreaks before local
authorities. During the 2003 SARS epidemic,
that spread from the Guangzhou province in
China to nearly 37 countries22, the first public
report of the epidemic was posted on ProMED
more than a month before the Chinese
government’s
official
announcement.21
ProMED’s membership is volunteer-based and
not affiliated with a governmental organization.
Therefore, they have greater freedom to report
what they observe than official organizations,
which may have political constraints on what they
can publicly report. This on-the-ground reporting
is thought to push governments to disclose more
information than they might normally.21
HealthMap (http://www.healthmap.org/)
is a newer surveillance system that continuously
monitors the internet, aggregating real-time
information on infectious disease outbreaks from
news media sources, blogs, and discussion
groups.23 HealthMap illustrates the distribution of
reported infectious diseases by superimposing
these incidents on a map of the world. The WHO
is one of its top users.23 This is significant
because it allows WHO to learn of emerging
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infectious disease without having to exclusively
rely on local public health agencies.
Conclusion
In summary, there are a variety of
infectious agents capable of causing disease in
humans. H5N1, a virus of avian origin capable of
crossing the species boundary to infect humans,
has the potential to cause the next influenza
pandemic and is thus of particular concern. In
order to adequately respond to the next outbreak,
frontline clinicians need to be eternally vigilant at
the community level. Furthermore, clinicians
must be aware of the need to act in a concerted
manner with other nations at the global level.
New technological advances should be fully
exploited to facilitate such globally coordinated
responses. The next pandemic will not observe
national boundaries, and our approach to the
control of EIDs should reflect an awareness of
this. The global community cannot afford to let
state boundaries prevent a necessary response to
the emerging pandemic threat posed by avian
influenza, or any other emerging pandemic threat.
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ETHICS
Drugresistant tuberculosis and the ethics of tuberculosis control
Christina Morgan (Meds 2011) and Hassan Mir (Meds 2012)
Faculty Reviewer: Dr. Lois Champion
Despite the declaration of tuberculosis (TB) as a global health emergency by the World Health
Organization in 1994, many in North America were unaware of the rapidly increasing health burden of TB
until the highly-publicized Andrew Speaker incident. Speaker, an American lawyer, knowingly left the
United States while infected with extremely drug-resistant TB and prompted an international health scare
which led to the first federal quarantine order since 1963. This incident highlights the growing concern of
emerging drug-resistant strains of tuberculosis, regarding which the WHO issued a global alert in 1996. It
also raises many issues meriting ethical examination, including public health measures to control TB,
individual obligation to avoid infecting others, and the role of the physician in infectious disease control.
The global health burden of tuberculosis
Historically a leading cause of human mortality,
tuberculosis was thought to be on its way to being
eradicated in North America as early as the
1950s. This decline was interrupted by a highly
publicized resurgence in New York City during
the 1980s and 1990s, primarily among homeless
and HIV positive individuals. The epidemic was
eventually brought under control in the 1990s
following enormous health care expenditure and
coercive public health measures, including
mandatory directly observed therapy (DOT) and
detention of patients who were noncompliant with
their prescribed treatment regimen.4 However,
TB has remained a significant issue all along in
developing nations; with one-third of the global
population infected with a latent form, TB is
currently the second leading infectious cause of
mortality worldwide.5
Prior to the Speaker incident, awareness of
the increasing global health burden of TB had
been largely overshadowed in Western society by
media focus on the HIV/AIDS epidemic. The
episode also highlighted the threat of emerging
drug-resistant
strains
of
tuberculosis.
Approximately 20 percent of worldwide TB cases
are identified as multi drug-resistant (MDR-TB),
and 10 percent of these are extremely drugresistant (XDR-TB).6 MDR-TB is defined as TB
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resistant to at least two of the four first-line
medications, namely isoniazid and rifampicin.
XDR-TB refers to MDR-TB, in addition to
resistance to fluoroquinolones and any one of the
second-line anti-TB drugs.6
The Speaker incident
Despite acknowledgement from the US Centers
for Disease Control (CDC) and the WHO of the
emergence and spread of extremely drug-resistant
TB (XDR-TB),7 the issue did not receive
extensive attention until Andrew Speaker became
a household name in May 2007. Speaker tested
positive for tuberculosis in January 2007,
following a pulmonary abnormality detected on
chest x-ray and CT scan, and a subsequent
diagnostic bronchoscopy, for which he was
prescribed a standard regimen of first-line
medications.2 He underwent susceptibility testing
at the Fulton County TB Clinic in Georgia
following the disclosure that he planned to travel
overseas for his honeymoon in May 2007. This
susceptibility, or sensitivity, testing was done to
determine the likelihood that his drug treatment
regimen would be effective in eliminating or
inhibiting the growth of the infection. The results
indicated that Speaker was infected with multi
drug-resistant tuberculosis.

Despite being advised by his primary care
physician and the Fulton County Health
Department that he should not embark on his
planned international travel, Speaker flew to
Europe without informing any public health
official. The discovery through further sample
analysis that he had XDR-TB prompted a nationwide border alert, and the Center for Disease
Control located Speaker in Rome and instructed
him not to travel on a commercial aircraft because
of the significant threat he posed to other
passengers. Despite this warning, Speaker flew to
the Czech Republic and then to Canada, having
correctly assumed that there was an order
preventing him from boarding any US-bound
flight. He reentered the US by automobile and
was promptly discovered by the CDC and served
the first provisional federal quarantine order since
1963.2
Public health versus individual liberty
One of the main ethical challenges highlighted by
the Speaker case is how to balance public health
concerns, which encompass the utilitarian aim to
promote the greater good, against the libertarian
aim of protecting individual rights and liberties.
Most would agree that neither public nor
individual interest should always be given
absolute priority over the other. The challenge,
therefore, lies in striking an ethically acceptable
balance between these two interests. Speaker’s
actions raise questions concerning the ethical
obligation of individuals to avoid infecting others,
which follows from the accepted ‘duty to do no
harm.’8 However, there must be limits to these
duties, as it would be excessive and virtually
impossible for all potentially infected individuals
to take all possible precautions to avoid infecting
others. There is no disputing that Speaker
behaved in an ethically inappropriate manner in
ignoring the health authorities’ traveling advisory.
One must also realize, however, that an ethical
obligation to avoid infecting others must involve
full understanding of the risk of infection. One of
the points of controversy in this case involves
Speaker’s allegations that he was initially simply
cautioned against, and not explicitly prohibited
from, traveling.8 Regardless of the truth of this
claim, we may learn from it that we, as health
UWO Medical Journal, Vol 78, Issue 2

care providers, can strengthen this ethical
obligation to avoid infecting others by making
certain the patient has full knowledge and
understanding of the risks involved in
undertaking a particular action. Relevant to this
case, these include knowledge of the transmission
of tuberculosis through airborne spread, the
nature of drug-resistant TB, and the dangers of air
travel and the risks posed to others.
It might also be possible that Speaker was
not adequately reassured that he would receive
acceptable care in Italy, or be returned to the US
in a timely manner for treatment. While he might
have been aware of the risk he posed to his fellow
travelers in returning to Canada, his sense of
ethical obligation might have been distorted
through a lens of fear following a frightening
diagnosis of extremely drug-resistant TB.
Although it is also entirely possible that his
actions were driven by selfishness and selfinterest rather than fear, the health authorities
could have endeavored to alleviate this fear by
assuring him of the quality of TB-related care in
Italy and providing him with a plan and timeline
for returning him to the US.
Another ethical challenge regarding TB
control, along with other infectious diseases,
follows from the concept that an individual is
both a victim of disease and a vector by which the
disease may be transmitted to the greater
population.9 How may we determine to what
extent isolation measures, namely the coercive
restriction of movement, are justified for the
purpose of TB prevention, and who should be
confined? Factors to consider in making these
decisions include whether or not the patient is
infectious and the risk the free movement of the
patient poses to the general population. There is
an obvious difference between confining someone
with active illness and refuses to take their
medication from someone with latent illness or a
very low risk of contagion. One of the ethical
failings in the control of the New York City TB
epidemic involved the confinement of
noninfectious patients who, although labeled as
‘recalcitrant’ for failing to take their medications
properly and to report for scheduled medical
appointments, posed no immediate infectious
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danger to others.4 One of the interesting aspects
of the Speaker case is that, although he was
infected with an XDR-TB strain, his level of
contagion was actually quite low, yet he was still
placed and kept under federal quarantine for
several months.2 It would not be unreasonable to
infer that the isolation measures were therefore
influenced by his noncompliant behavior and the
threatening nature of his diagnosis, as opposed to
strictly his level of infectious risk. As physicians,
we should advocate for appropriate diagnostic
tests to assess the patient’s level of infectivity and
for evidenced-based isolation measures that are
appropriate to the risk posed by the patient.
Fear-Driven Public Health Measures
Smith, Battin et al. discuss the ethics of public
health decision-making regarding infectious
diseases in context of their overwhelming ability
to provoke fear and panic in populations.9 They
argue that this fear can lead to emotionally-driven
decision making that challenges basic medical
ethics principles such as autonomy and social
justice. In certain instances, the results of these
decisions may be positive. For example, during
the New York TB outbreak, the decision to
institute mandatory directly observed therapy was
motivated by the recognition of drug-resistant
strains of the disease that were more difficult to
eradicate, and this eventually helped to stem the
outbreak. However, in other instances, feardriven public health procedures may come into
conflict with bioethical principles or even basic
human rights. South Africa’s current policy
involves enforced quarantine of patients with
drug-resistant TB in prison-like hospitals with
high fences patrolled by guards to prevent
escape.10 Although the country is battling the
highest global TB prevalence with a concurrent
HIV/AIDS epidemic, some patients are required
to spend several years in hospital, long past the
point of infectiousness. Several recent studies
have ascertained that these hospitals can, in fact,
serve as breeding grounds for drug-resistant TB,
such that patients with MDR-TB are contracting
XDR-TB strains at an alarming rate.11 Thus, not
only is this enforced quarantine a challenge to
patient autonomy and human rights, but it is
posing additional risk to the patients and is a huge
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financial burden on an already weak health care
infrastructure.
The enormity of the media attention the
Speaker case received, as well as the issue of the
first federal quarantine in over 40 years,
highlights the panic and fear that the emergence
of drug-resistant tuberculosis has engendered in
Western society. Given that his actual contagion
was low, one must wonder whether the nature of
his diagnosis with XDR-TB and the fearful
response provoked by his actions influenced the
health authorities’ decision to take extended
isolation measures. This highlights our role as
physicians in an era of mass media coverage to
put infectious diseases and epidemics into context
for the general public, and to assuage community
hysteria when it is disproportionate. We have an
ethical obligation to help our patients understand
the severity of a situation, such as the danger
posed by travel with infectious disease, but must
also help public health authorities to minimize
fear-driven decision making that is non-evidencebased or ethically suspect.
Social Justice in Tuberculosis Control
Another interesting aspect of the Speaker incident
involves the fact that the case of one infected
individual traveling through the developed world
could generate so much media attention and bring
the issue of drug-resistant TB to the global stage,
when it has been a serious problem all along in
developing nations. Speaker does not resemble
the typical TB patient in that he is a wealthy,
white, educated male from a developed country.
Infectious diseases affect primarily the poor and
developing world due to lack of sanitation and
weak healthcare infrastructure, among other
factors. When making public health decisions
that may pose ethical challenges and infringe
upon individual rights and freedoms, it is
important to consider the nature of the population
these decisions will affect. As developing nations
are oppressed by virtue of their economic
position, and will shoulder the burden of public
health measures for the control of tuberculosis, it
is important to give consideration to individual
rights where possible, as the “blame, stigma, and
ostracism associated with isolation and quarantine

are especially real for diseases linked to the
poor… or the disenfranchised.”2
Conclusions
Though by no means exhaustive, the ethical
issues highlighted with respect to the Speaker
incident illustrate the need for ethical reflection in
developing public health policies for tuberculosis
control. Drug-resistant tuberculosis, which has
now become a global threat, is largely propagated
in poor countries where poverty and a weak
health care infrastructure often preclude finishing
a full course of TB treatment. Improved health
care provision in endemic areas would therefore
reduce the frequency by which we would have to
make public health decisions that challenge
individual rights and freedoms. The role of the
physician must involve providing the patient and
the public with appropriate and adequate
information in order to strengthen individual
obligation to do no harm, as well as to prevent
community panic and emotionally-driven decision
making which can lead to public health policies
that infringe upon the rights of the individual.
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HEALTH PROMOTION
Infection prevention myths demystified
Laura Hinz (Meds 2011) and Jennifer N. Bondy (Meds 2012)
Faculty Reviewer: Dr. John Howard
In the mid-20th century, industrialized countries underwent the ‘epidemiological transition’ whereby the
leading cause of death evolved from infectious and parasitic to chronic and degenerative diseases.11 This
transition, however, has not yet occurred in many developing countries.11 In 2002, infectious and parasitic
diseases caused the greatest burden in disability-adjusted-life years (DALYs) to human beings worldwide.16
Although the threat of infectious and parasitic diseases in developed countries such as Canada has
decreased since the middle of the last century, protecting ourselves against such diseases should remain a
priority since we reside in a global community. We take this opportunity to explore three “urban legends”
of day-to-day infection prevention and determine whether there is truth to these myths.
Hand towels vs. air dryers
The Myth
The Centres for Disease Control and
Prevention (CDC) has a list of recommendations
regarding hand-washing, which includes drying
hands using a paper towel or air dryer.23 This step
in the procedure has sparked considerable debate
in the infectious disease realm. Are paper towels
or air dryers more effective? Proponents of
towels argue that you may as well not wash your
hands if you insist on using air dryers as they just
blow the germs back on. Proponents of air dryers
lament the environmental impact of towels.
Unfortunately, the literature is similarly divided
on the issue.
The Evidence
Early studies on this topic were strongly in
favour of hand towels. In 1984, one of the first
comparisons of the two drying methods found
that paper towels could reduce bacteria on hands
by 55% while air dryers achieved a dismal 9%
reduction.4 Subsequent studies found towels to be
safer and more hygienic than air dryers,6,7 while
one study even found that not only were air dryers
less effective, but they actually increased the
number of microorganisms left on hands.4
Uncertainty began to mount in 1991 when
a study in the American Journal of Infection
Control reported that air dryers were more
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effective in reducing the numbers of Escherichia
coli and rotavirus from hands.3 The argument was
levelled when a randomized control trial
conducted in 2000 failed to find a significant
difference in bacterial numbers when the use of
rotary dispenser towels, stacked paper towels, air
dryers, and spontaneous evaporation were
compared.2 It is interesting to note that in a
separate study, it was found that hands that were
held stationary under the dryer retained fewer
bacteria than rubbed hands.4 This difference was
explained by the fact that rubbing allows bacteria
to migrate from the hair follicle to the skin
surface, thus the finding may simply be a
measurement bias. Nonetheless, they concluded
that stationary hands under an air dryer was the
best method, followed by a tie between paper
towels and rubbed hands.4
When investigations were broadened from
microbes remaining on hands to microorganisms
in the washroom environment, the equivocality
remained.4 Taylor et al concluded that in
bathrooms equipped with paper towels, the germs
were transferred from the hands to the towels,
which were then disposed of in open receptacles
where they acted as reservoirs of bacteria. In
contrast, while the air dryers killed a sizable
proportion of microorganisms by virtue of the
heater, the splattering of water droplets onto the
wall behind the dryer made this one area of the

bathroom to avoid. This dispels the myth put
forth by towel proponents: air dryers do not just
concentrate microorganisms from the air onto the
users’ hands, as evidenced by the fact that dryer
outflow contained significantly fewer organisms
than inflow.4
The Verdict
Despite the controversy, all studies were
in agreement about the importance of hand
washing. Proponents of towels can argue using
evidence from early literature, the finding that
paper towels were more effective in removing
bacteria from the fingertips in particular1 and the
CDC recommendation that one use a paper towel
to turn off the tap.23 They may also argue that air
dryers are not recommended in critical care
environments due to the possibility of air
dispersal of bacteria-laden droplets.8 Air dryer
enthusiasts can cite findings from more recent
studies, environmental considerations, and the
capacity to remove bacteria from the air.
However, there is no clear victor in this debate.
The important takeaway points are to wash your
hands well; if you choose a towel, dispose of it in
a closed receptacle; if you choose an air dryer, try
to use an automatic model and don’t rub your
hands.
Antiseptic hand sanitizers vs. soap and water
The Myth
Since
Semmelweis’
groundbreaking
observations in 1847 that proper hand sanitization
measures can reduce infection rates, health
professionals have been provided with procedures
and guidelines aimed to perfect the hand washing
process.4 These guidelines are applicable both in
the hospital and the community since hands serve
as the main vector for micro-organism transfer.6
However, poor compliance with hand hygiene has
been attributed to a variety of factors including
lack of time and skin irritation.22 Antiseptic
sprays and rubs have been introduced as a means
to confront these problems, however the question
remains: do the new methods work as well as
traditional hand-washing?
The Evidence
Hand-washing involves the use of plain
soap and water to clean hands, whereas antiseptic
UWO Medical Journal, Vol 78, Issue 2

hand-washing employs a soap containing an
antiseptic agent, which differs from an antiseptic
hand rub in that the latter does not require water.25
Plain (non-antimicrobial) soaps are an
effective means by which to reduce both the
transient bacteria colonizing the superficial layers
of skin and the transmission of these pathogens.24
These soaps do not, however, remove the resident
flora found in the deeper layers of skin.24 Prior to
surgery, antiseptic hand-washing scrubs are
typically employed, as these are more effective in
eliminating bacteria.25 Some centres have
introduced pre-surgical rubs, further highlighting
the inconclusive nature of the literature.
With respect to hand rubs, chlorhexidineand alcohol-based products are two common
varieties. Chorhexidine rubs are efficient in
eliminating gram positive bacteria, but are not as
effective for gram negative bacteria and
nonenveloped viruses.25 Further, certain bacteria
have been demonstrated, in vitro, to adapt and
develop resistance against chlorhexidine, leading
to resistance to other anti-infective agents.24 The
epidemiological implications of these findings in
humans are not yet fully understood and require
further study.25
Conversely, while alcohol-based rubs
have minimal residual activity25 and do not
effectively eliminate bacterial spores, protozoan
oocytes or certain nonenveloped viruses25, there
have been no reported cases of acquired
resistance to these rubs. Furthermore, alcohol
does prevent the transfer of certain nosocomial
pathogens and effectively reduces bacterial load
on hands.25
The Verdict
Conflicting evidence exists in the
literature as to the effectiveness of the various
antiseptic agents used for handwashing, which is
due in part to the fact that not all studies assess
effectiveness in the same manner.26,27 However, a
review by the CDC found agreement among
studies that alcohol-based handwashes and rubs
are more effective in eliminating bacteria on
hands than plain soap, and often more so than
antimicrobial soaps.25 Their effectiveness,
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however, is dependent on a variety of factors
including the type, concentration, and volume of
alcohol used.
Plastic water bottles
The Myth
Plastic water bottles have recently been
the subject of much debate in the media. The
litany of offences attributed to the vessels include:
acting as a reservoir for germs, leaching toxic
chemicals, and posing unnecessary stresses on the
environment.10,13,18 Waterloo has banned the sale
of plastic water bottles in schools and Toronto
appears poised to follow suit in 2009.18 Despite
these controversies, bottled water continues to be
a $35 billion industry, with 1.7 billion gallons
consumed last year (nearly 3000 Olympic
swimming pools’ worth).17
This exorbitant
consumption also means that 150 million water
bottles are disposed of each day.9 A seemingly
probable solution would be to reuse the water
bottle, but the literature suggests that this
environmentally friendly solution could wreak
havoc on our health.
The Evidence
Researchers in Calgary selected an
elementary school as their source of water bottles
for analysis in 2002.10 They found that total
coliforms exceeded Canadian Drinking Water
Quality guidelines in 13.3% of water bottles
examined; 8.9% contained fecal coliforms, and
64.4% contained heterotrophic bacteria. While
heterotrophic bacteria are not necessarily
pathogenic, they are a marker of overall water
quality.20 Some of the students had left water
bottles for months without a proper cleaningsignificantly longer than the eight hours that the
literature suggests it takes for bacterial
regrowth.10 When combined with the finding of
no significant microbial content of water sources
(taps and fountains), the researchers determined
that the germs were coming from the bottles.
Several studies have suggested that plastic
water bottles provide a better breeding ground for
bacteria than glass or metal.12 Plastic bottles tend
to contain fast-growing bacteria (pseudomonads,
Flexibacter, and Acinetobacter), numbering in the
realm of 105 cfu/mL after one week of growth.12
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In contrast, glass bottles contained slow-growing
bacteria (mainly Acinetobacter) and were an order
of magnitude less in quantity. Not only is the
type of material important, but the quality. Jones
et al. isolated mainly coccoid bacterial cells from
the caps of plastic water bottles, while rod-shaped
cells were found adherent to the walls of PET
bottles.15 Rougher surfaces were associated with
a significant increase in bacterial numbers.
The issue in the Calgary study was not the
use of plastic water bottles, but the subsequent
reuse. Both nonpartisan researchers and the
Canadian Bottled Water Association have
established that bottled water does not contain
E.coli, coliforms, Giardia, or cryptosporidium at
the time of bottling.13,19 The real problem lies in
the fact that water at room temperature is an ideal
environment for microbial growth. A simple
solution would seem to be meticulous washing of
the water bottles. However, this solution was
discredited by a 2001 presentation by a University
of Idaho student who found that realistic reuse
simulation (sunlight, heat, physical degradation)
released a number of chemicals from the plastic
water bottles into the drinking water.13 The longer
water bottles were reused, the more organic
chemicals were leached from the material.
The environment vs. health debate has
thus seemingly reached an impasse- reusing water
bottles is good for the environment but sets up a
bacterial breeding environment, necessitating
vigorous cleansing, which in turn liberates toxic
chemicals. One appears to have the choice
between infection, intoxication, or pollution.
The Verdict
The evidence is fairly clear that water
bottles pose a threat both to human health and to
the environment. However, a little common sense
may go a long way in settling the clash of values.
Soft-plastic water bottles such as those sold in
vending machines should not be reused as their
ability to stand up to the vigorous washing needed
in order to prevent colonization has not been
established. Hard-plastic, glass and metal water
bottles may be more well suited to the challenge
of multiple uses and their use is condoned by the
Minister of Health Canada.21 Water bottles

should be thoroughly washed in hot soapy water
after each day of use.
It is very difficult to come to generalized
conclusions as to the safety of water from
municipal taps and from rural wells as compared
to bottled water. The importance of the presence
of trace amounts of chemicals in tap water as
compared to bottled water is not known.
Moreover, the entire picture needs to be examined
– the energy required in making, bottling, and
distributing bottled water is immense and this
may impact not only the individual consumers,
but also the health of human populations. The
safety of the individual must be weighed with the
potential harm the use of water bottles has on the
environment. For water bottles, whether single
use or washed multi-use, the evidence is
inconclusive.
Three common societal beliefs have been
discussed that may impact our lives as individuals
or as a population. This paper attempted to use an
evidence-based
approach
to
make
recommendations. It is also important to review
the evidence as a whole to consider the threats to
the individual, to the people in the immediate
environment, and to the broader global
community. Given the human health importance
of hand-drying techniques, hand sterilizers and
water bottles, it is suggested that the apparent
simplicity of these issues not deter future
research.
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HISTORY OF MEDICINE
Erythema infectiosum, fifth disease, and parvovirus B19: how did they
get together in the first place?
Michael Livingston (Meds 2011) and Kate MacKeracher (Meds 2012)
Faculty Reviewer: Dr. Paul Potter
The purpose of this paper is to provide a detailed overview of how and when the associations between
erythema infectiosum, fifth disease, and parvovirus B19 were established. Attention will be paid to the
discovery of a “milder form of rubella” in 1889; the naming of erythema infectiosum in 1899; the
emergence of the name “fifth disease” in 1905; the discovery of parvovirus B19 in 1975; and the eventual
linking of erythema infectiosum and parvovirus B19 between 1983 and 1985.
Introduction
Erythema infectiosum is a common rash-like
illness that often occurs during childhood and is
caused by parvovirus B19.1 It is also known as
“fifth disease” and “slapped cheek disease,” the
latter of which refers to the condition’s
characteristic, red rash. While most medical
students will cover these details at some point in
their medical training, they may never know how
the connections between erythema infectiosum,
fifth disease, and parvovirus B19 were
established, and where these terms come from.
Why is erythema infectiosum called the
“fifth” disease anyway? A Wikipedia article on
the topic states that “The name… derives from its
historical classification as the fifth of the classical
childhood skin rashes or exanthems.”2 In typical
Wikipedia style, however, no explanation is
provided.
Even more legitimate resources do little
else to clarify this issue. Up-to-Date, the bastion
of evidence-based medicine, notes that “Erythema
infectiosum is… referred to as ‘fifth disease’
since it represents one of six common childhood
exanthems, each named in order of the dates they
were first described.”3 But just like its unreliable
counterpart, Wikipedia, no other details are given.
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The purpose of this paper is to: (1) clearly
describe how and when erythema infectiosum was
first discovered; (2) explain how and when it
became known as fifth disease and why this name
is perhaps inappropriate; (3) describe the
coincidental discovery of parvovirus B19; and (4)
explain how the connection between parvovirus
B19 and erythema infectiosum was finally made.
The discovery of erythema infectiosum
Erythema infectiosum was first described in 1889
by Tschamer, who thought it represented a milder
form of rubella (German measles).4 Additional
cases were described by Gumplowicz in 18915
and by Tobeitz in 1898.6 According to a review of
cases presented by Shaw in 1905, the first person
to suggest that this infection was a separate
clinical entity was Escherich in 1896.7
This condition didn’t actually become
known as erythema infectiosum, however, until
1899, when it was given that name by Georg
Sticker, a Professor of Medicine at Giessen
University, Germany.8 Sticker’s description
included the lack of perceptible fever at the time
of presentation and emergence of red patches on
the cheeks, consisting of large symmetrical
blisters with red halos. The following day, the
rash spread to the lower arms and thighs, as well
as over the trunk, forehand, temples. This
secondary rash consisted of round red spots or
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larger, irregular, red patches (see Figure 1).
Sticker noted that these eruptions tended to be
slightly raised and that they were better felt than
seen. These symptoms were most apparent on the
third or fourth day of the infection and then
rapidly resolved.

any confusion with scarlet fever, measles, or
rubella (German measles). Sticker’s description of
erythema infectiosum ends with an interesting
acknowledgement: “In trying to find the specific
cause we have been just as unsuccessful as other
researchers have been with other kinds of kinds of
infectious exanthems.” Indeed, the medical
community would have to wait almost a century
before the causative agent would finally be found.
Sticker’s
description
of
erythema
infectiosum had such an impact that for many
years it was known simply as “Sticker’s disease.”
Even as the term “fifth disease” became more
common in some parts of the world, the reference
to the Professor’s name persisted in Germany for
years to come.
It began with the fourth

Figure 1: Classic presentation of erythema
infectiosum (fifth disease) in a child aged 16
months. Note the smooth rash on the cheeks and
lace-like pattern (secondary rash) on the rest of the
body.

Sticker
observed
how
erythema
infectiosum spread through families and was
consequently able to confirm its contagious
nature. He also suggested that it belongs to the
group of so-called “acute exanthems,” but that its
particular course and skin symptoms excluded
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The origins of the name “fifth disease” go back to
1885, when a Russian physician named Nil
Filatow was working on another childhood
exanthem. His work was read at the Moscow
Medical Society meeting on November 20, 1885,
and later in published in German.9 As with
Sticker, the list of childhood exanthems
established up until this time included measles,
scarlet fever, and rubella (German measles).
Filatow argued for the existence of a fourth
exanthem, which he called rubeola scarlatinosa.
He reasoned that if patients could get this disease
after having already had scarlet fever, or if
contracting this disease did not protect them
against getting scarlet fever in the future, then
scarlet fever and rubeola scarlatinosa must be two
different things. Filatow had seen evidence of this
happening in one set of patients and appealed to
doctors working in larger institutions to provide
further evidence for the existence of this clinical
entity.
One such doctor came along several years
later named Clement Dukes. Dukes was a
physician at a Rugby school in London, England,
where he believed he had seen many patients
similar to those described by Filatow. In 1894, he
published an article in the Lancet in which he
referred to rubeola scarlatinosa as epidemic
roseola or rose rash.10 (This is not to be confused

with roseola infantilitis, which was described in
1910 and later became known as sixth disease.11)
Dukes went into great detail describing
what he believed were clear differences between
scarlet fever, rose rash, and measles. He conceded
that “In their elucidation they have entangled
many of the ablest physicians, to our professional
discredit and to the detriment of the welfare of
our schools,” but insisted that “… They are as
separable as typhus and typhoid fever.”
Dukes published a second article on this
topic in 1900.12 In this paper, he noted that he “…
would not venture to suggest an appropriate name
for this disease,” and referred the question of
nomenclature to the Royal College of Physicians
of London. “Pending this authoritative decision,”
Dukes “… tentatively employ[ed] the general
expression of the ‘fourth disease.’” Ironically, this
name not only became permanently associated
with rubeola scarlatinosa, but it also initiated a
numbering system for the classic childhood
exanthems that remains to this day.
The naming of fifth disease
Today, the fourth disease is regarded by most as a
non-entity.13 In spite of the detailed reasoning
presented by Filatow and Dukes, other studies
could not establish that the fourth disease exists
independently of scarlet fever, measles, or
rubella, nor could a causative agent be
determined. The most obvious flaw in the
Filatow-Dukes logic is the fact that it is possible
to get scarlet fever more than once.14 Thus, the
idea that an infection confers immunity, and that
any future infection that looks like scarlet fever
must be something else, is incorrect.
Still, the idea of the fourth disease lasted
long enough for the naming of fifth disease
several years later. In 1905, a French physician
named Cheinisse described erythema infectiosum
in a weekly periodical called La Semaine
Medical. He made reference to the three classic
diseases of childhood: scarlet fever, rubella, and
measles, and mentioned the so-called fourth
disease, rubeola scarlatinosa, in his introduction.
His subsequent description of erythema
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infectiosum was entitled “Une cinquème maladie
éruptive: le mègalérythéme épidémique” (i.e., a
fifth eruptive disease: the infectious erythema). It
is unclear when exactly this name was changed to
simply fifth disease, but the basis of its numbering
can be traced back to Dukes “general expression
of the fourth disease” in 1900.
The fact that fourth disease is now
considered a non-entity suggests that the name
fifth disease is perhaps inappropriate. While it is
true that it was discovered after fourth disease,
this numbering system makes the false
assumption that Filatow-Dukes’ disease actually
exists.
The discovery of parvovirus B19
Early attempts to connect erythema infectiosum
with its causative agent included the inoculation
of supposedly infected human sera in monkey
renal cells.15 In another attempt, researchers
obtained blood samples, throat swabs, and stool
or rectal swabs from 27 infected patients and
looked for pathological changes in various tissue
cultures.16 Neither of these studies were
conclusive. Another researcher went so far as to
suggest that the causative agent of erythema
infectiosum wasn’t infectious at all, but that
correlation with the use of a margarine emulsifier
indicated that it was based on nutritional and
personal factors.17
Given the clinical course of erythema
infectiosum (see Figure 2), it is easy to see why it
was so difficult to identify its causative agent,
parvovirus B19. While it is true that the lifetime
prevalence of this virus approaches 90%, the
viremia occurs before the emergence of the
characteristic, red rash, and then rapidly resolves.
Furthermore, the symptoms during the prodromal
period are mild and non-specific. Many other
cases are asymptomatic throughout the entire
infection. It should be no surprise then that the
discovery of parvovirus in human blood occurred
coincidentally.
The human parvovirus was discovered by
someone who had no interest in erythema
infectiosum whatsoever. While working in
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Figure 2: Schematic representation of the clinical course and laboratory abnormalities in normal hosts with
parvovirus B19 infection. Note the biphasic timing of symptoms, during the peak viremia and again after the
viremia has cleared. Rash, arthritis, and other symptoms typically associated with parvovirus B19 occur during the
second period.2

virologist named Yvonne Cossart came across a
collection of parvovirus-like particles while
screening blood samples for hepatitis B.* The
sample containing these particles happened to
occupy position 19 on plate B, which eventually
led to the name B19.
Parvoviruses had long been known to
infect cats, rats, mice, minks, dogs, pigs, rabbits,
geese, and cattle.18 But up until Cossart’s
discovery, there was no evidence for parvovirus
infection in humans. As a result, researchers were
initially reluctant to refer to B19 as a true
parvovirus, opting for terms like human
parvovirus-like agent (PVLA)19 and human serum
parvovirus-like virus (SPLV)20 instead.

*

Cossart later discovered the presence of parvovirus in the
serum of a patient diagnosed with acute hepatitis. This
coincidence raised the possibility of parvovirus being the
elusive non-A, non-B virus. This, of course, turned out to be
not the case, with hepatitis C being discovered several years
later.
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The search for the causative agent of erythema
infectiosum was so elusive that it actually ended
up taking place the other way around. Following
Cossart’s discovery in 1975, a microbiologist
named Anderson was busy studying parvovirus
B19 at King's College Medical School in London.
In 1982, he noted that “Infection with PVLA
[parvovirus B19] is an apparently common event,
occurring most often in childhood. Studies…
show that that peak of antibody acquisition occurs
between the ages of 4 and 6 years, and by the age
of 16 one-third of subjects have PVLA
antibody…”19 He also noted that “… three of the
four blood donors from Dr Cossart’s group of
nine who were followed up became ill shortly
after giving blood; two complained of fatigue
which was in one individual accompanied by
leucopenia, while the third developed a rash.”19
As seen in Figure 2, these symptoms and sequelae
are classic to erythema infectiosum.

In 1983, this same researcher, obviously
aware of what a parvovirus B19 infection might
entail, provided epidemiological evidence of a
parvovirus being the cause of erythema
infectiosum.21 This connection was aided by a
coincidental outbreak in north London and the use
of parvovirus-specific IgM radioimmunoassay to
confirm true cases.20,22 Further evidence on this
outbreak was provided in 1984.23
The final confirmation of parvovirus B19
being the cause of erythema infectiosum occurred
when seronegative volunteers were inoculated
with parvovirus from an asymptomatic donor.24
One week after inoculation, symptoms included
mild illness, malaise, and other non-specific
complaints, as well as viremia, excretion of the
virus from the respiratory tract, and decreased
levels of hemoglobin, reticulocytes, lymphocytes,
neutrophils, and platelets. 17 to 18 days later, a
second-phase of the illness with rash and sore
joints lasting three days occurred in three of the
four infected volunteers. (Refer to Figure 2 for an
overview.) This constellation of symptoms was
consistent with erythema infectiosum and
explained why parvovirus infection could cause
aplastic crisis in patients with chronic hemolytic
anemia (such as sickle cell disease).
Conclusion
The associations between erythema infectiosum,
fifth disease, and parvovirus B19 evolved
gradually over almost 100 years. The turning
points in this history include: (1) the recognition
of a “different form of Rubella” by Tschamer in
1889; (2) the naming of erythema infectiosum by
Sticker 1899 (and the evidence for its
independence from scarlet fever, measles, and
rubella); (3) the influence of Dukes and his
general expression of fourth disease in 1900; (4)
the reference to a fifth disease by Cheinisse in
1905; (5) the discovery of parvovirus by Cossart
in 1975; and (6) the evidence of parvovirus as the
causative agent by Anderson from 1983 to 1985.
It is true that some of these details amount
to little more than historical trivia. But it is the
authors’ hope that this overview will give
students a greater appreciation of erythema
UWO Medical Journal, Vol 78, Issue 2

infectiosum, fifth disease, and
causative agent, parvovirus B19.

its

elusive
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INTERDISCIPLINARY COLLABORATION
Lessons from the listeriosis outbreak
Abhijat Kitchlu (Meds 2011) and Allanah Li (Meds 2012)
Faculty Reviewer: Dr. John Howard
Introduction
The recent outbreak of listeriosis has been called
the worst epidemic of this illness that the world
has ever seen.1 To date, there have been 53
confirmed cases across Canada and 20 confirmed
deaths in which listeriosis has been the underlying
or contributing cause of death.2 Despite the
August 24, 2008 recall of over 220 different
products, concerns of continued spread persist in
the wake of a November 22 warning from the
acting chief medical officer of health regarding
the discovery of Listeria monocytogenes in seven
provincial correctional facilities.3, 4 Given the
magnitude of this outbreak, criticisms of the
responses of all parties involved have been
inexorable. The Public Health Agency of Canada
(PHAC), the Canadian Food Inspection Agency
(CFIA) as well as Maple Leaf Foods and other
corporations have all been faulted as the toll of
this outbreak continues to rise.5 Although
opinions differ where, if at all, blame should be
laid, most would agree that the listeriosis outbreak
has given Canadians cause to examine one of the
most vital areas of collaboration in our health care
system – the interaction between the various
organizations which safeguard our food.
Overview of the outbreak
As early as June 2008, Toronto Public Health
Units noticed a minor increase in the number of
reported listeriosis cases. By mid-July Toronto
Public Health increased their investigations after a
listeriosis case was discovered in a Toronto
nursing home. Food samples from the nursing
home were sent to Health Canada labs and on
August 5, 2008, a sandwich was found to be
contaminated with Listeria. Toronto Public
Health then notified the CFIA of the positive food
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samples and on August 12 Maple Leaf Foods was
informed by the CFIA that a formal investigation
of their products was underway. CFIA officials
met with public health officials two days later and
the decision was made to stop serving certain
meat products in hospitals and long-term care
facilities. On August 16 the CFIA and Health
Canada met and recommended a recall on certain
Maple Leaf products. The following day Maple
Leaf announced a voluntary recall of some
products from their Toronto plant; over the period
of August 17 – 24 the list of recalled products
grew to 220 as the number of listeriosis cases and
associated deaths continued to rise. The recalled
products also included prepared sandwiches by
other corporations including Lucerne Meats,
Atlantic Foods Ltd. and Metro Ontario Inc.
During this time Maple Leaf Foods’ Toronto
plant was shut down to undergo cleaning and reevaluation of safety practices. The Public Health
Agency of Canada announced on August 23 that
tests confirmed the link between the listeriosis
outbreak to Maple Leaf Foods and the following
day television ads begin airing featuring Maple
Leaf CEO Michael McCain’s apologies on behalf
of the corporation.6, 7
Since then, the Public Health Agency of
Canada has been continually issuing updates on
the number of confirmed and suspected cases.
However, critics of the Ministry of Health and
Long-Term Care (MOHLTC) and PHAC would
argue that Michael McCain, rather than acting
Chief Medical Officer of Health, Dr. David
Williams or Chief Public Health Officer, Dr.
David Butler-Jones, has been the major public
figure informing Canadians about the outbreak.5
Similarly, critics of the CFIA have lambasted
2007 reforms that allowed the food industry itself
a much greater degree of self-monitoring.
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Considering both the controversy about the
management of the outbreak and the extent of its
spread Prime Minister Stephen Harper announced
an investigation into the outbreak. This
investigation includes an evaluation of the
“efficiency and effectiveness of the response by
federal agencies in terms of prevention, the recall
of contaminated products, and collaboration and
communication among partners in the food safety
system and the public”.1
The following discussion will examine the
major agencies involved and review some of the
criticisms elicited by the epidemic.
The Public Health Agency of Canada and the
chief public health officer
The Public Health Agency of Canada (PHAC)
was created in the aftermath of the SARS
outbreak of 2003. It was initially its own ministry,
with a cabinet seat reporting directly to the Prime
Minister. However, in 2006 the government
eliminated the ministry and cabinet position and
relegated the Chief Public Health Officer to a
civil service position under the Minister of
Health.5
The tasks of the agency include preventing
both chronic disease and outbreaks of infections.
The latter task falls primarily under the Infectious
Disease and Emergency Preparedness (IDEP)
branch. This branch contains the subdivision
known as the Centre for Infectious Disease
Prevention and Control (CIDPC), which is
responsible for public health surveillance and
epidemiological studies during foodborne
epidemics. The National Microbial Laboratory
(NML) and the Laboratory for Foodborne
Zoonoses (LFZ) are also involved in outbreak
surveillance and provide pathogen strain
differentiation and other analytical services.8
As per the current Canada Foodborne
Outbreak Response Protocol, the PHAC and
specifically the CIDPC has the responsibility of
“communication with the public as it relates to the
public health implications of the epidemiological
investigation”, until a food source has been
identified, at which point the CFIA “will have the
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lead for public communications as it relates to the
food safety investigation and any necessary food
safety recall activities”.9 Despite the specificity of
this protocol, critics have suggested that the Chief
Public Health Officer failed to act as “the leading
national voice for public health, [particularly] in
outbreaks and other health emergencies”.5 Some
have noted the greater relative prominence of the
Minister of Agriculture and Agri-Food Canada
and Michael McCain of Maple Leaf Foods during
the outbreak. Such criticism has led to concerns
about the independence of the Chief Public
Health Officer, who may be constrained by
prevailing political considerations. As he or she
serves under the Minister of Health and has less
protection from dismissal than similar positions in
the United States and United Kingdom, some
have questioned this officer’s ability to raise
public health concerns without fear of political
repercussions. The independent investigation
initiated by the Prime Minister will be able to
assess the efficacy of the PHAC and the Chief
Public Health Officer given their current
apparatus and whether the agency acted with due
diligence. However, new concerns are being
raised that “the investigator will not have any
power to subpoena witnesses or documents; the
investigation will be closed to public
participation; and there is no commitment to
publish the investigator’s findings or report to
parliament”.1
The Canadian Food Inspection Agency and the
role of industry
The Canadian Food Inspection Agency (CFIA)
reports to the Minister of Agriculture and AgriFood and is responsible for protecting the safety
of Canada’s food supply. The CFIA implements
surveillance and inspection programs intended to
provide an early warning for problems within the
food supply. In the event of a food safety
emergency, the CFIA works in partnership with
Health Canada, provincial agencies, and the food
industry to operate an emergency response
system, including food recalls.10
Inspection of ready-to-eat meat products,
such as the contaminated cold cuts at the centre of
the listeriosis outbreak, was formerly done by

CFIA inspectors. However, a Canadian
government review of the CFIA in November
2007 resulted in various reforms to inspection
policy. Of particular importance was a decision
that effectively transferred inspection duties to the
meat industry, with government inspectors taking
on more of an oversight role.1 This decision
meant that inspectors spent less time on plant
floors conducting visible inspections and more
time analyzing data collected by industry.11
Maple Leaf Foods was an early supporter of these
inspection reforms.1
The push towards greater industry selfregulation has not received universal support.
Those who argue in favour of self-inspection say
that industry has greater incentives to ensure safe
products for their customers and are more likely
to develop new scientific testing technologies and
protocols.11 Those who argue against selfinspection say that industry is more concerned
with profits than product safety. They are
concerned that tests may not be performed
adequately, results may be altered, or government
inspectors may be denied full access to the data.11
The listeriosis outbreak has affected the
operations of both the CFIA and Maple Leaf
Foods. Dr. Brian Evans, CFIA Executive VicePresident and Chief Veterinary Officer of Canada,
has conceded that the agency should have done a
better job communicating with the public during
the outbreak.12 The CFIA is also revising its
Listeria surveillance protocols to ensure greater
transparency and more protection for consumers,
including reinstating a rule compelling companies
to inform inspectors of positive Listeria tests.13
For its part, Maple Leaf Foods estimated the
outbreak and following recall cost the company
over $25 million directly and another $14 million
in lost sales.14 Moreover, the results of a classaction lawsuit filed against the company are yet to
be determined. Following the outbreak, Maple
Leaf Foods toughened its own policies regarding
Listeria, to a level more rigorous than the
proposed CFIA protocols.13
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Conclusion
Despite the many criticisms of all parties involved
in the listeriosis outbreak, it remains unclear as to
where the prevention and response systems failed.
In fact, it can be argued that all parties responded
adequately given the circumstances. Further
investigations by the government may yield
valuable recommendations to improve the
response to foodborne illness and the safety of the
food supply, provided that such investigations are
thorough, objective, and transparent. However,
the listeriosis outbreak has already demonstrated
the importance of rapid communication and
collaboration between private industry and all
levels of government to ensure the health and
safety of the public.
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MEDICINE AND THE LAW
Pushing the envelope on organ donation
Abdullah Alabousi (Meds 2011)
Faculty Reviewer: Dr. Joaquin Madrenas
In June 2007 a Dutch television station
broadcasted a program in which a terminally ill
patient interviewed three potential candidates in
order to select one of them to receive her
kidneys.1 The choice of recipient was to be made
on the basis of the contestant’s history and
profile, as well as based on conversations with
their family and friends; viewers were also able to
add their input via text messages. As expected,
medical professionals and politicians were
outraged when the program was aired. Soon after,
it was revealed that the show was a hoax intended
to raise awareness about the shortage of organ
donors; the donor was in fact an actress, while the
three potential recipients were genuine. Even
though the impact of the program on the public
and on government policy is difficult to assess, it
does bring to our attention the fact that there is a
significant worldwide shortage in the supply of
donated organs for those in need.1 In fact, just like
most other developed nations, Canada has been
unable to keep pace with the demand for organs.
This issue of organ shortage is worth exploring in
order to be able to make conclusions about the
causes and possible solutions.
The Situation in Canada
In order to assess the extent of the problem in
Canada it is important to review some of the
available statistics. For instance, 4,195 Canadians
were on wait-lists for organ transplants on
December 31, 20072 compared with 3974 people
on Jan 1, 2006 and 2592 people in 1995.3 Only
2188 transplants were performed in 20074 and
193 Canadians died waiting for an organ
transplant in the same year.2 Moreover, according
to the Canadian Organ Replacement Registry,
Canada’s cadaveric donation rate for deceased
donors in 2005 was 12.8 per million inhabitants,
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which falls well below the rates in countries like
Spain (35.1), Estonia (26.5), Belgium (22.8), Italy
(20.9) and the United States (21.5) as projected by
the International Registry maintained at the
University of Barcelona, Spain.3 On the bright
side, living donation rates in Canada are rising
and currently stand at 15.6 per million
inhabitants. Nevertheless, there are significant
regional variations in deceased and living organ
donation rates. Deceased donations range from
5.1 in Manitoba to 17.9 in Quebec. Living
donations range from 7.0 in Quebec to 19.9 in
Alberta.3 There are also significant provincial
variations in wait times for transplants. In fact, a
recent study of 7034 dialysis patients found
people under 40 waited a median 8 years in
Ontario for a new kidney, compared with 3 years
for those in Alberta.5 Hence, not only does
Canada have a shortage in organs, the nation also
possesses a very fragmented system that has led
to regional variations in organ donation rates as
well as provincial variations in wait times for
transplants.
One of the problems of the Canadian
system is that less than half of the organs that
could potentially be transplanted are actually
harvested. There are a number of reasons for the
inefficiency including the fact that in many cases
the family members of an individual are simply
not approached for consent. In addition, there is
no concerted effort and little resources allocated
to educate Canadians about the benefits of organ
donation.4 However, the main problem with the
Canadian system lies in the presence of many
fragmented organ donation programs that are so
varied that it is difficult if not impossible to
characterize national practice in Canada as a
whole.3 The existence of many organizations and
programs that vary from province to province is a

“reflection of the fractured jurisdiction over
health care”.3 In fact, it has been suggested that
Canada’s low organ donation rates maybe be
partly due to a lack of a coordinated and
centralized approach to dealing with the issue.3
New Developments
In recent months there have been attempts by both
federal and provincial governments in Canada to
make policy changes that will reduce the shortage
of organs available for transplantation by
attempting to decrease the fragmentation and
improve the coordination and communication
amongst the provinces. In fact, one very recent
positive development with regards to organ
donation in Canada was an agreement reached in
August 2008 between the federal, provincial
(except Quebec) and territorial governments to
develop an “integrated national organ donation
system” 6, including national oversight and
allocation mechanisms for all donated organs and
tissues. Prior to this initiative, Canada was the
only developed country without a national
transplant system, which has resulted in a
significant variation in organ donation rates
across the country and a lack of equal access to
life-saving transplants.4 Under the new funding
arrangement, the Canadian Council for Donation
and Transplantation (CCDT) has merged with
Canadian Blood Services, which has expanded its
mandate and operations to include organ and
tissue donation and transplantation.2 While the
fragmented provincial transplantation agencies
will continue to run independently, more effort
will be put into improving the co-ordination
amongst the different agencies.
The initiative is further aimed at creating
and managing three electronic registries: the
Urgent Status Registry to ensure patients most
desperately in need of organs are treated first,
regardless of where they live; the Living Paired
Exchange Registry to facilitate the donation of
organs such as kidneys and lungs by living
donors; and the Intent to Donate Registry to coordinate the various provincial programs that
allow potential donors to give their consent to
donate organs when they die.4 The creation of
these registries will not only reduce the
UWO Medical Journal, Vol 78, Issue 2

fragmentation in our approach to organ donation,
it will also provide us with much needed data and
evidence to allow us to better evaluate our
progress. In addition to the national organ-sharing
network that will be created, there will also be
efforts directed at standardizing consent policies
and creating nationwide wait lists for all available
organs. Mandatory organ sharing and other
requisite elements of a national organ donation
and transplantation program will be phased-in
over a number of years.6
Alternative options
At the present time, Canada utilizes an “opt-in”
approach to organ donation. An individual needs
to give consent by signing an organ donation
card, or explicit consent needs to be obtained
from surviving family members before a person’s
organs can be used after their death.3 This
approach to organ donation has proven to be
suboptimal when it comes to harvesting organs to
give to those in need. In fact, Canada possesses a
legal framework that does not promote organ
donation.
An alternate strategy would be a
“presumed consent” (opt-out) approach, whereby
everyone is presumed to be a donor unless they
have specified otherwise in advance.3 There are
two main variations of this policy that have been
utilized in some European countries.
For
instance, Spain, a world leader in organ
donations, has managed to achieve the highest
organ donation rate in the world by implementing
a policy of “soft” presumed consent whereby
relatives may opt-out for a dying patient.7 In
addition, the Spanish government invested
heavily in educational campaigns and “transplant
support teams”7 who provide emotional support
to bereaving families, helping decrease refusal
rates. Since the implementation of the “soft”
presumed consent approach in Spain in 1990,
donation rates have doubled to their current level
of 35 per million. Another variation of this policy
is the “hard” presumed consent policy seen in
Austria where relatives may not opt-out for a
dying patient. This approach began in Austria in
1982, and since then, their donation rate has
quadrupled to 25 donors per million.7 Ontario
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rejected the presumed consent approach on the
grounds that Canadian society “is not ready”3;
however, it is difficult to say whether or not the
government has the right to judge if the people
are or are not ready for a new approach to organ
donation. Still the Ontario government is not
sitting idle and is considering the idea of “first
person consent”, whereby an organ is
automatically harvested when a donor card has
been signed, with no consideration for the opinion
of the donor’s family.3
As effective as presumed consent appears
to be, however, simply changing organ donations
laws and regulations will not solve Canada’s
shortage of organs. What is needed in addition to
changing the laws is a significant shift in attitudes
toward organ donation. In Spain for instance,
considerable emphasis is placed on organ
donation awareness. There is special funding and
training provided for transplant teams, who are
responsible for working with grieving family
members to explain the situation and explain to
them the value of organ donation. Furthermore,
the general public needs to be educated about the
importance of signing their organ donation cards,
and about the many lives they can save if they
choose to do so. Without such a system of
education and counseling for grieving families, a
presumed consent law will not live up to its
potential.7
In addition to presumed consent, there are
a number of other strategies that can possibly be
implemented to address the shortfall in donated
organs. These include monetary incentives for
those who signup to be a donor. For instance,
making an offer to the family to reimburse the
donor’s funeral expenses. Other incentives could
include providing priority access for previous
donors in the event they need an organ.3
Conclusion and Future Outlook
All in all, Canada has had a dismal record when it
comes to organ donation and that must change
sooner rather than later because the demand for
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organs has been growing over the years. The
federal and provincial governments have taken
some positive steps in recent years to try to
improve the situation; the most significant step
has been the plan to develop an integrated
national organ donation system, including
national oversight and allocation mechanisms for
all donated organs and tissues. However, more
needs to be done to correct the current state of
affairs. This could involve amending the current
laws and regulations pertaining to organ donation,
educating the public and raising awareness about
the importance of organ donation, as well as
providing incentives for those who agree to
donate their organs. Until such time we can only
look with admiration towards countries such as
Spain, which has become a world leader when it
comes to organ donation.
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MEDICINE AND TECHNOLOGY
Applications of Nanotechnology in Infectious Disease
Pencilla Lang (Meds 2011) and Jenny Shu (Meds 2012)
Faculty Reviewer: Dr. Jana Jass
Nanotechnology is a major recent technological development affecting medical approaches to disease
treatment and immunity induction. For example, nanoparticles can be used to create anti-microbial agents
and vaccine adjuvants to target difficult microbes such as HIV, Salmonella, Tuberculosis and Listeria.
While this new technology makes lofty promises, it is important to keep in mind the possible biological and
environmental hazards of nanoparticles. In the coming decade, physicians will be called upon to make both
treatment and policy decisions regarding the use of nanoparticle technology.
Introduction
For those who are not “nanotechnology”
scientists, the word appears to be much of an
enigma, conjuring up science fiction style images
of micromachines, computer chips and
lithography. Richard Feynman may not have been
thinking about battling infectious diseases when
he coined the famous quote “There's plenty of
room at the bottom”, but there is certainly plenty
of room for nanotechnology in our campaign
against microbes.
Despite the fact that nanotechnology is
rapidly changing the face of medicine, many
physicians are still unable to define it. The US
National Nanotechnology Initiative defines
“nanotechnology” as “understanding and control
of matter at dimensions of roughly 1 to 100
nanometers, where unique phenomena enable
novel applications”.1 In the past, engineers were
confined to using naturally occurring materials
and forming them through industrial processes.
Material properties frequently constrained device
designs. Nanotechnology allows materials to be
custom-designed on a molecular scale and enables
the design of new and different devices.
Like much of medicine, our battle with
infectious disease has been one of broad sweeps
because it is difficult to target microbes and
components of the immune system with high
specificity. Treatment has been caught in a
UWO Medical Journal, Vol 78, Issue 2

perpetual tug of war attempting to balance the
dangers of illness against the damage incurred by
therapy. The immune system is a perfect example
of molecular machinery at its most complex.
Nanotechnology provides the opportunity to meet
microbes and our immune systems at a molecular
level. While there are many potential applications
for nanotechnology in the area of infection and
immunity, some of the earliest and most
promising developments have been in the
development of antimicrobial agents and new
vaccines.
Antimicrobial Agents
Nanoemulsions are oil-in-water droplets ranging
from 200-600 nm2. These are high energy
droplets thermodynamically driven to fuse with
lipid-containing organisms.
The electrostatic
attraction between the cationic charge of the
emulsion and the anionic charge on the pathogen
enhances the fusion. When fusion occurs, the
active ingredients inside the particle and the
energy released in the fusion process destabilize
the lipid membrane, resulting in cell lysis and
death. These antimicrobial agents can be used in
wound irrigation and decontamination of highrisk surfaces (for example in hospitals). Studies
have shown these agents to be effective against
bacteria (E. coli, Salmonella, S. aureus), viruses
(HIV, Herpes), and fungi (Candida).2
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Nanoparticles are also used to deliver
antimicrobial agents. A microscopic carrier hides
and protects molecules from degradation in the
body, and allows it to be delivered to specific
target cells in a controlled manner.3 Alternatively,
special “carriers” can be designed to carry
therapeutic agents across membranes into specific
intracellular compartments and through the bloodbrain barrier. These areas have traditionally been
difficult to reach.4 Research in this area began in
the early 1990s, and has since expanded to
encompass treatment of many intracellular
infections, including fungal and parasitic
infections,
Listeria,
Salmonella
and
5,6
Tuberculosis.
Nanoparticle carriers can be
metallic, lipid-based, polymer-based or biologic
(resembling a virus).6
Silver particles have long been known to
be bactericidal. Recent research on silver
nanoparticles have demonstrated them to be quite
promising against new strains of bacteria resistant
to current antibiotics, and gram negative bacteria,
including E coli, V cholera, P aeruginosa, and S
typhus.
The
bactericidal
properties
of
nanoparticles are size dependent, with particles 110nm having the best direct interaction with
bacteria. Silver nanoparticles act primarily in
three different ways. Nanoparticles attach to the
surface of the cell membrane and disturb its
function, rhey penetrate the bacteria and interact
with DNA, and they release silver ions which
have a separate bactericidal effects.7
Vaccine Development
The effectiveness of a vaccine is measured by its
ability to interact with, and stimulate, the immune
system. The nano-engineering of vaccines allows
the creation of better adjuvants and vaccine
delivery systems. Currently, nanoparticles are
being used in the design of nasal and
transcutaneous vaccines. A nasal vaccine attempts
to generate an immune response by exposing the
nasal
mucosa
to
antigens.
Similarly,
transcutaneous vaccines target the immature
dendritic cells (professional antigen-presenting
cells) found in high density in the epidermis and
dermis of the skin.
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Traditionally, nasal vaccines have had
limited effectiveness because free antigens are
readily cleared from the nasal cavity, poorly
absorbed by nasal epithelial cells, and generally
have low intrinsic immunogenicity. Encapsulation
of the antigen into bioadhesive nanoparticles will
allow these particles to be tailor-made with
specific ligands, adjuvants and endosomal escape
mediators. Some of the promising nasal vaccines
underdevelopment
include
vaccines
for:
Parainfluenza, Hepatitis B, Measles, Yersinia
pestis, and HIV.8, 9, 10, 11
Particular attention is being paid to the
HIV vaccine. Since HIV targets immune cells in
an unusual way, standard approaches to an HIV
vaccine have been met with limited success.
Vaccines administered in the nose to induce
mucosal immunity are also able to induce
immunity in the genital mucosa. Development of
mucosal immunity may play an important role for
protection against HIV, as it allows the body to
mount an immune response early on in the disease
process.8 The production of IgA antibodies on
mucosal surfaces is unique to mucosal
immunization. Mucosal immunization will
stimulate both the mucosal and systemic immune
responses (systemic immunization will only
induce the systemic response), improving vaccine
efficacy.12
Current transcutaneous particle-based
vaccines are made of naturally occurring
“particles” and can vary in quality from batch to
batch and induce adverse events. Manufactured
nanoparticles can be topically applied to hair
follicles.13 In a similar fashion to the nasal
vaccine, this technique uses nano-sized inert solid
carrier beads to covalently bond antigen.14
In both the nasal and transcutaneous
vaccines, particle characteristics are important
determinants of the effectiveness of the vaccine.
Nanoparticles allow particle characteristics to be
designed to specification. It also allows for a
systematic study of the effects of parameters such
as particle size, shape, and charge.15
Nanoparticles approximately 10m in diameter
are selectively uptaken by cells in Peyer’s patches
in the gut. It is postulated that particles

resembling the size of viruses will trigger a viraltype immune response (cellular), whereas
particles the size of a bacterium are more likely to
trigger a humoral response. Smaller nanoparticles
are also more rapidly absorbed by nasal mucosal
cells. Since epithelial cells carry a negative
charge, a positively charged nanoparticle should
be more effective than a negatively charged
particle.16

past 10 years, and this is expected to continue
well into the future.18 Most significantly, the
Nanomedicine Initiative of the National Institutes
of Health Roadmap for Medical Research
initiative predicts that nanomaterials will begin
yielding significant medical benefits within the
next 10 years.19 Diagnostic application of
nanoparticles are also important for rapid
treatment to some infections.

With
all
the
hype
surrounding
nanotechnology, physicians need to be prepared
to address patient concerns regarding the new
vaccine designs. Some questions they should be
prepared to answer include: Are these vaccines
fundamentally different from those used in the
past? What potential problems may arise from
their use? How do they differ, in terms of risks,
effectiveness and adverse events from other
vaccines?

Nanotechnology – Friend or Foe?

Other applications
With clinical applications of nanoemulsions and
nanoparticle vaccines already in use, it is not
difficult to imagine other potential applications of
nanotechnology in immunology. Drug delivery
systems designed to interact with tissue in
specific locations and times are currently being
used in engineering. These systems should allow
for more accurate targeting of therapeutic agents
– allowing greater therapeutic effects through
increased activity, and decreased adverse effects.
These medications take advantage of the ability to
control molecular structure to allow for enhanced
activity.16 Perhaps most fantastic of all is the idea
that scientists may eventually be able to create
special pieces of machinery that imitate the
immune system to destroy specific targets, in
essence manufacturing artificial “antibodies” that
can be administered to patients as anti-microbial
agents.17 While these prospects may appear to still
be speculations of the future, it is not too early for
physicians to be preparing for their eventual
integration
into
mainstream
medicine.
Pharmaceutical companies are already actively
pursuing and preparing for this major change in
how therapeutic agents will be delivered and
work. Published patent applications in this area
have increased at a near exponential rate in the
UWO Medical Journal, Vol 78, Issue 2

While nanotechnology holds a lot of promise, it is
important not to overlook the potential problems
and hazards that this technology may pose. The
creation of new materials may impart unintended
novel chemical properties that may be harmful to
human health. These may be difficult to identify
in short-term clinical trials.20 In recent years, the
significance of nanotoxicology has started to
become recognized and studied. Nanotoxicology
has developed into its own emerging discipline,
including its own international conference,
NanoTox, which emerged in 2007 to study the
potential problems arising from the use of nanosized particles, materials and machines, and
potential solutions.21 Another recent study from
the Woodrow Wilson Centre's Project on
Emerging Technologies concluded that there is
limited understanding of the effects of
nanotechnology on human health.22 Physicians
will have a significant role in the management of
these problems.
There are also major political, economical,
environmental and social ramifications associated
with this technology. For example, the small size
of particles, combined with potentially novel
chemical properties, poses a question of how
ingested but non-metabolized particles may be
collected and properly disposed of. In addition,
the effects of such particles on the environment,
and the environmental impacts of production
processes have not been adequately studied.23 As
a major stakeholder in nanovaccines and
nanoemulsions, physicians will be looked upon
by governmental and regulatory agencies to
comment on the balance of benefit and hazards
posed by these materials.
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Developments in nanotechnology have
opened up many new approaches to treating and
preventing infectious disease. Nanoparticle antimicrobials and vaccines are examples of how this
new technology is likely to be used in the coming
decade. Physicians will have a major role in
policy-setting, technology implemention and
answering the questions of a concerned and
curious public.
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PROFILES
An Interview with Dr. Marina Salvadori
Julie Hughes (Meds 2012) and Emma Love (Meds 2011)
Faculty Reviewer: Dr. Marina Salvadori
“Part of what drives people in infectious diseases is that we find some international and tropical diseases
just fascinating… We’re often people who like details, we’re good at trivial pursuit – that’s just the nature
of who we are. Part of what drives us is that there really are no borders in the world, and disease does not
stop at a border. There is a famous quote that says, ‘There is nowhere anymore from where we are distant,
there is no place that is remote.’ Infectious diseases affect all of us.”
Dr. Marina Salvadori is passionate about fighting
infectious diseases, and with good reason.
Infections have been a driving force of history in
fields as diverse as politics, economics, and art.
Alexander the Great died prematurely of a lung
infection, the bubonic plague contributed to the
shift away from European feudalism, and
tuberculosis helped to shape the Romanticist
movement. Part of the tried-and-true fabric of
medicine, in Dr. Salvadori’s words, Infectious
Disease is “about advocacy, about global health,
about “stamping out disease and pestilence.”
Dr. Salvadori is a pediatric infectious
diseases specialist active in advocacy work, with
a particular focus on the promotion of
vaccinations. Her medical career started in the
Queen’s University medical class of 1991, which
she followed with a pediatrics residency in
Winnipeg:
“I decided when I was about 12 that I
wanted to be a doctor, probably because I
absolutely loved my family doctor.
I
thought he was the most wonderful person
in the world and I just thought it would be
such a fun thing to do. I also was raised in
a family that had a tremendous sense of
social justice and social responsibility, so I
knew my final career choice had to have an
aspect like that…
At first I did pediatrics, and I think that was
because I grew up in an immigrant family
UWO Medical Journal, Vol 78, Issue 2

and had no cousins or grandparents or
anything, so the oldest people I knew were
my parents, who were 46 when I went to
medical school… When I did pediatrics I
felt a sweeping sense of relief.”
It may reassure current medical students and
residents that, while she is happy in her current
work, her choice of careers was not without a few
bumps along the road:
“Once I was in pediatrics I realized that I
had very poor technical skills and I’m not
good with my hands, which I did know
beforehand, but it was emphasized in
pediatrics! I’m what I call a cognitive kind
of doctor. … If I had known about
community medicine and public health, I
may well have done that.”
When asked about a typical day, she responds that
answering such a question is impossible:
“That’s what I like about being a pediatric
infectious diseases specialist – the fact is
there actually is no such thing as a typical
day! By the nature of infectious diseases,
most things are very acute, so when I get up
in the morning I have no idea what I’m
going to have to deal with that day… On a
given day I can’t predict my patient load, I
can’t predict what kinds of problems I’m
going to see, and that is partly why I do

Page | 39

academic medicine and why I do infectious
diseases.
I do various things… teaching medical
students and residents, teaching other
health care professionals, interfacing with
public health on policy development,
working on national advisory committees
for immunizations, traveling… What’s most
rewarding is when I’m part of national and
provincial decision-making that comes out
with a policy that actually has a huge
health impact that nobody sees or knows
about.”
Such contributions include advocating for the
infant pneumococcal vaccine for Ontario–a
relatively low-profile health policy change that
has nonetheless had a significant impact on health
for all. Dr. Salvadori’s work consists of a
remarkably diverse collection of endeavours,
including some international health initiatives:
“I’ve had some fabulous opportunities. I
joined a group from UBC and did some
teaching of pediatric infectious diseases
doctors in China, because they don’t have
infectious diseases as a specialty, and after
SARS thought they should. A large Hong
Kong donor asked that Canada be part of a
training program for these people. I went
there to teach and some of them have come
here, and that was a wonderful experience.
I’ve also been asked to do policy
development for a pediatric oncology
hospital in Egypt, because they’re trying to
get a pediatric oncology care for the Arab
world. They needed someone to help adapt
policies to their situation, and that was
really interesting.”
Dr. Salvadori continually emphasizes the need for
“big picture” thinking in medicine. When asked
about challenges she faces on an individual basis,
she comments not on obstacles associated with
patient care, but on policy issues. In particular,
she highlights the importance of developing
nationally driven policies rather than fragmented
provincial guidelines, and alternative financing
models that encourage physicians to be involved
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in advocacy and preventative medicine. She also
comments more broadly on the challenges facing
the world of infectious diseases:
“There are so many. There’s the HIV
epidemic, which is changing the political
and economic landscape of Africa. There’s
tuberculosis coming out as multi-drug
resistant. There’s global warming, which is
dramatically affecting the habitats of
animals and then changing how the
microbes they carry interface with humans,
so we’re getting all kinds of new infectious
diseases emerging…. If you look at a global
picture, infectious diseases are still the
number one killer of people and the number
one health care issue. If you look at our
very privileged North American society,
infection control is becoming more and
more paramount in hospitals, as are
infection-related illnesses from drug
resistance.”
I also have to say that the implementation
of vaccination programs with growing
groups of vaccine naysayers, who could
actually lose all the ground we as a society
have gained in the fight against infectious
diseases, is a huge challenge…. There are a
lot of challenges, and certainly a lot of
work to be done.”
Nonetheless, she has high hopes for the future,
and a firm belief that there will be world changing
scientific advances within this generation:
“Another rewarding aspect [of my work] is
vaccine evaluation and development that
has the potential—and I know this sounds
grand—to change the face of disease in the
whole world. The Human Papilloma Virus
vaccine and cervical cancer is one such
vaccine. Rotavirus vaccine is another. We
lose 600,000 children in the world a year
and now that vaccine has been developed.
To be part of guidelines for its use really
makes me feel that we can have a local,
provincial, national, and global impact….

We’re doing very well. AIDS in Africa is
really difficult, but there will be an effective
vaccine. It will happen. We all want it
tomorrow, but if it’s in 20 or 30 years,
that’s a very small timeframe in the history
of the world. I think it will be before that,
and then we can really make a difference.
When you look at it, vaccination is the only
thing that we as a global community
endeavour to at least offer to every global
citizen. There is nothing else.”
Many infectious disease specialists see global
health as an essential obligation as well as a way
to re-ignite their initial passion for their field. Dr.
Salvadori sees new possibilities in this area as a
result of increased funding:
“I look to some of my colleagues, who in
the latter part of their careers, do fantastic
projects
with
the
World
Health
Organization. They’ve done immunization
implementation that’s rational and that you
can apply to the local culture and situation.
I’m really inspired and driven by that kind
of work. I tell people that before the
internet and computers—before any kind of
mass communication—we as a global
community eradicated smallpox. We can
do that for other diseases, like polio, and
we actually can conquer these as
humankind.
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The Bill and Melinda Gates Foundation has
the largest impact in the infectious diseases
world, particularly in developing nations
and immunization initiatives, of anyone
else. They have given $800 million a year,
which is the exact same budget as the
World Health Organization. Some of my
colleagues who have toiled away in
unknown parts of Africa on obscure
diseases with $20,000 grants have now
been able to make huge steps forward. For
these people, it wasn’t intellect, drive, or
ability, but money that stopped them from
reaching their potential.”
In sum, both abroad and at home, Dr. Salvadori
seeks to fulfill the dual roles of the physician as
health care provider and patient advocate:
“For me, being an infectious diseases
doctor, advocacy and patient care are so
intertwined, and so much a part of what I
do.
Advocating for appropriate
immunization schedules for infants actually
takes care of my patients as a whole
because then they don’t get infectious
diseases. I cannot separate my professional
roles of advocacy, teaching, and immediate
patient care on an individual level because
they’re so intertwined in who I am and how
I practice medicine.”

Page | 41

THINKING ON YOUR FEET
Pediatric Pneumonia
Kalpa Shah (Meds 2012) and Aiman Alak (Meds 2011)
Faculty Reviewer: Dr. Michael Rieder
Case

Etiology/Causative Agents

Accompanied by his mother, seven-year-old John
presents with worsening non-productive cough
and fever. Two days ago, he was diagnosed with
an upper respiratory tract infection at a walk-in
clinic and prescribed amoxicillin; however, his
condition did not improve. His past history is
negative for allergies, asthma, cardiovascular
disease, and cancer. However, his mother recalls
about 5 similar episodes over the years. John was
born at term, and his immunization is up-to-date.

Pediatric pneumonia is a significant cause of
morbidity and mortality worldwide causing two
million deaths yearly.1-5 In North America, the
annual incidence of pneumonia ranges from 15 to
45 per 1000 children, depending on the particular
age group. Although not a major cause of
mortality in North America, pneumonia in
children is a major source of morbidity.

On physical exam, his oral temperature is
38.2oC, his heart rate is 95 beats per minute, his
respiratory rate is 35 breaths per minute, and his
blood pressure was 100 over 60 mmHg. The child
is occasionally coughing, but does not appear
toxic.
A chest radiograph revealed left lower
lobe consolidation consistent with a diagnosis of
pneumonia. John was treated with clarithromycin
and improved over the next two days.

In planning therapy knowing the
responsible pathogen is a key element in
designing the therapeutic plan. The best predictor
of the causative agent is age (Table 1).6-8
However, even in prospective research studies,
the pathogen could not be identified in half of the
cases, and in the clinical setting blood cultures of
children with pneumonia are commonly negative.
As the determination of the causative pathogen is
difficult, empirical therapy is the common
treatment course for children with pneumonia.

Table 1: Causative agents based on age group.
Age
Causative agents (in descending order of frequency)
Birth to 20 days

Group B streptococci, gram-negative enteric bacteria, cytomegalovirus, Listeria
monocytogenes

3 weeks to 3 months

Chlamydia trachomatis, respiratory syncytial virus, parainfluenza virus 3,
Streptococcus pneumoniae, Bordetella pertussis, Staphylococcus aureus

4 months to 4 years

Respiratory syncytial virus, parainfluenza viruses, influenzavirus, adenovirus,
rhinovirus, Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma
pneumoniae, Mycobacterium tuberculosis

5 to 15 years

Mycoplasma pneumoniae, Chlamydia pneumoniae, Streptococcus pneumoniae,
Mycobacterium tuberculosis, influenza A or B, adenovirus, other respiratory viruses
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Risk factors
Risk factors that increase the incidence or severity
of pneumonia in children include: prematurity,
malnutrition,
low
socioeconomic
status,
attendance at day-care centers, passive exposure
to smoke, pollution or toxic fumes.9 Inhalation of
harmful substances contributes to lung
inflammation and damages cilia function, thereby
reducing the ability of the lungs to clear
themselves, thus making them more prone to
infection. Also, children whose immune systems
are compromised by illness, immunosuppressant
drugs or chemotherapy have a higher risk of
contracting infections.10
Clinical Assessment
Pneumonia should be suspected when a child
presents with fever and one or more signs of
respiratory distress including grunting, nasal
flaring, rales, retractions, wheezing or
tachypnea.11 It has been suggested that tachypnea
is the best indicator a child has pneumonia rather
than an uncomplicated upper respiratory tract
infection.12 The most commonly used guidelines
for assessing tachypnea are that of the World
Health Organization’s and are as follows: for
children one to five years of age a respiratory rate
of more than 40 breaths per minute and in
children older than five years more than 30
breaths per minute signifies tachypnea.13
Measurement of tachypnea requires a one full
minute count while the child is quiet. Pneumonia
is unlikely in patients without fever and more than
one respiratory sign.14 In patients with respiratory
distress but no fever, a reactive airway disease,
aspiration of a foreign body, or underlying
pulmonary or cardiac disorder should be
considered.
It should be mentioned that classically two
presentations have been described for pneumonia:
 Typical pneumonia: fever, chills, pleuritic
chest pain and a productive cough.
 Atypical pneumonia: gradual onset over
several days to weeks, dominated by
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symptoms of headache and malaise,
nonproductive cough and low-grade fever.
However, clinically it is often difficult to
distinguish between these two presentations.
Also, it is not possible to distinguish whether the
cause of pneumonia is viral or bacterial based on
clinical signs alone.15
Diagnosis and Testing
The main support for a diagnosis of pneumonia
comes from the patient history and physical
examination. A chest radiograph is considered by
many to be the gold standard for confirming a
diagnosis of pneumonia.16 However, there is some
controversy regarding the utility of using chest xrays to distinguish between causative organisms.
Classically lobar infiltrates were associated with
bacterial infections and interstitial filtrates are
thought to be indicative of viral infections.
However, both lobar and interstitial filtrates have
been found in viral, bacterial and viral-bacterial
infections. Some studies flatly state there is no
relation between the appearance of the chest x-ray
and the causative agent.17 Whereas, others claim
there is some value in using radiological features
to distinguish between bacterial and viral
etiologies.18
When additional information is required to
help decide whether antibiotics are necessary a
WBC and differential count may be useful.19 The
pneumonia is likely of bacterial origin if the WBC
count is elevated (typically greater than 15 000)
with predominance of polymorphonuclear cells.20
If the child is more than 10 years of age and is
able to produce sputum a Gram stain test and
culture of the sputum can be used to help identify
the cause.21 For Mycoplasma and Chlamydia
species serologic testing for IgM or increase in
IgG titres may be useful.22 However, serologic
testing is often of little use in the immediate
treatment a patient, and usually provides only a
retrospective diagnosis to determine the cause of
an outbreak.
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Table 2. Empirical antimicrobial therapy for pediatric pneumonia depending on age and severity.*

Age group
Outpatients
Hospitalized patients
3 months to 5 years Amoxicillin, erythromycin, Cefuroxime
or clarithromycin

Patients in intensive care unit
Cefuroxime plus erythromycin
or clarithromycin

5 years to 18 years Erythromycin or
clarithromycin

Cefuroxime plus erythromycin
or clarithromycin

*Adapted from Jadaviji T, et al (1997)10

Erythromycin or
clarithromycin with or
without cefuroxime

In most children with community acquired
pneumonia identification of the causative
organism is not critical. However, in cases where
the patient has severe symptoms, is not
responding to treatment or if there appears to a
community outbreak, the responsible organism
should be determined.
Management
As mentioned above, identifying the causative
agent is difficult. Thus, the current Canadian
guidelines for the treatment of Paediatric
pneumonia, established in 1997, approach the
problem from an age based, etiologic
perspective.23
The consensus group suggest therapy
based on age and the most common causative
agents. They favoured antibiotics with the
cheapest price, narrowest spectral range,
minimum side effects, and ease of compliance.
These guidelines allow for flexibility based on the
overall clinical presentation, and the local
resistance patterns of predominant bacterial
pathogens. The consensus groups add that the
scarcity of well-conducted randomized controlled
trials make their recommendations weak.
Most moderate forms of pneumonia could
be treated with oral agents, while intravenous
administration is reserved for patients with severe
pneumonia requiring hospitalization. Children age
less than 6 months, children with toxic
appearance, children requiring supportive therapy,
or children not responding to oral antimicrobial
therapy should probably be admitted to the
hospital. The recommended therapy based on age
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group and pneumonia severity is summarized in
Table 2.
An important part of treatment is
supportive care, including hydration, antipyretic
therapy and oxygen as necessary. As well, the
child should be monitored and follow-up arranged
to determine if therapy has been successful or if
therapy needs to be re-evaluated.
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ZEBRA FILES
Genitourinary tuberculosis: a rare but potentially devastating disease
Jenna Ashkanase (Meds 2011), Anna Burianova (Meds 2012), and Ashley Brown (Meds 2011)
Faculty Reviewer: Dr. Peter Cadieux
Extrapulmonary manifestations of tuberculosis (TB) are an uncommon but important disease entity.
Genitourinary (GU)-associated infections in particular occur mostly secondary to those of the lungs, but can
also occur as primary infections through infected clothing or even via sexual transmission. Two case
reports, one of a man with a cutaneous penile tuberculous ulcer, and the other of his wife who later
contracted endometrial TB, illustrate the latter route of transmission. While penile ulcers in men and
infertility in women have long differential diagnoses, it is important to keep in mind that extrapulmonary
TB is a possibility, especially in patients from TB endemic areas. Investigations of these disorders should
therefore include a full TB workup in patients in whom TB is a possibility, including Mantoux testing,
histopathology looking for caseating granulomas, and chest radiography to differentiate between primary
and secondary genitourinary TB. Given the serious complications of genitourinary TB, including sexual
dysfunction in men and infertility in women, it is extremely important to effectively recognize and treat GU
manifestations of TB.
Introduction
Although the majority of primary tuberculosis
(TB) occurs in the lungs, approximately 20% of
infected patients will develop an extrapulmonary
manifestation over time. The genitourinary (GU)
tract is the most common site for extrapulmonary
TB, with the most frequently affected sites within
the GU tract being the epididymis (42%), seminal
vesicles (23%), prostate (21%), testes (15%) and
vas deferens (12%) in males, and the fallopian
tubes in females.1,8 The first cases of
genitourinary TB were described in the 19th
century, in which they occurred as a complication
of routine infantile circumcision, after which TBinfected surgeons sucked the bleeding penis, thus
transmitting the disease to the infant. Now
however, other methods of transmission to the
GU tract are being described.
Amongst all GU-associated TB infections,
penile cutaneous TB is extremely rare,
comprising less than 1% of all cases in males.2 It
may manifest as primary, secondary, or
papulonecrotic
tuberculide
type.
Primary
infection may be acquired by direct inoculation of
the mucosa through contaminated skin or
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clothing. Secondary infection, on the other hand,
refers to disseminated TB occurring after
infection of other organs in the genitourinary
system or arising from haematogenous spread
from the lungs. Lastly, papulonecrotic tuberculide
type is a subset of secondary infection,
representing an allergic reaction to bursts of TB
antigen reaching highly immune-sensitive skin
following haematogenous spread from an internal
nidus (such as the lungs).4 Of the three types of
transmission, primary is thought to be the most
rare. Sexual transmission has been recognized as
a legitimate mode of primary spread with
important implications for reproductive health, as
demonstrated by the following case reports.3
Case 1
A 50-year-old Indian man living in the United
Kingdom presented with a painless, indurated
ulcer near the penile corona after a recent trip to
India. The lesion had been present for two
months and had increased in size to measure 1 cm
in diameter and 1 cm in depth at the time of
examination. Left inguinal lymph nodes were
palpable and non-tender, but no additional local
or systemic symptoms were present.

Presentation
Investigations began with a punch biopsy
that was negative for penile carcinoma, however
granulomas of an unknown cause were revealed.
Urine tests, chest radiograph, and abdominal
ultrasound were unremarkable. The patient did
not consent to HIV testing, but stated that his wife
had been his only partner for the past 25 years.
An excisional biopsy demonstrated the presence
of caseating granulomas which produced
Mycobacterium tuberculosis on culture.
The initial treatment regimen was
combination therapy of isoniazid, rifampicin,
pyrazinamide, and pyridoxine for two months.
Isoniazid and rifampicin were then to be
continued for an additional four months. The
ulcer regressed and did not recur. Although
screening conducted by the Public Health
Department in Oxfordshire could not uncover
other cases of TB in the patient’s family, the
patient’s wife did not consent to genitourinary
screening.
Case 2
The 49-year-old wife of the patient in Case 1
presented with menorrhagia, fever, sweats, and
weight loss one year after her husband’s diagnosis
of penile TB.
An endometrial biopsy was
obtained and revealed multiple caseating
granulomas of an unknown cause. She had no
known previous infection with TB, but had been
having unprotected sexual intercourse with her
husband prior to his diagnosis. Urine and
abdominal ultrasound results were unremarkable,
but an inactive calcified granuloma in the left
apex of the lung was discovered. A second
biopsy of the endometrium was performed and
culture produced M. tuberculosis. Following this
discovery,
restriction
fragment
length
polymorphism analysis was performed and
confirmed that both husband and wife had been
infected by identical organism, thus making this
the first confirmed case of sexually transmitted
TB.
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Clinically, TB of the penis generally presents
either as superficial ulcers of the skin or glans of
the penis, or as tuberculous cavernositis
(inflammation of the cavernous bodies).4, In most
cases, the lesion appears as a superficial ulcer on
the glans or around the corona, as this is the most
common part abraded during sexual contact or
with infected clothing.2,7 The normal penile
mucosa is highly resistant to tuberculosis, but in
the case of sexual transmission, the bacilli are
inoculated into abrasions caused by vigorous
sexual activity.7 Although the glans and corona
are most commonly affected, the lesions can also
be extensive, with involvement of the urethra and
corpus cavernosum, and rarely may even present
as hardened nodules.2 Male patients with penile
tuberculosis can present with impotence, and
advanced cases may also present with erectile
failure due to tuberculous caveronositis.3,7
Female genitourinary tuberculosis is
associated with infertility, although diagnosis is
difficult since patients are usually asymptomatic.
Some women (such as the one in the preceding
case reports) do however present with symptoms
such as menorrhagia, fever, sweats, weight loss,
and malaise.
Making the diagnosis
The differential diagnosis of chronic penile ulcer
with histological features of granulomas is
extensive, and thus diagnosis of penile disease
can often be difficult.3 Consideration needs to be
given to bacterial and fungal infections (such as
syphilis and herpes simplex), parasitic infections,
vasculitides, inflammatory bowel disease,
sarcoidosis, penile carcinoma, foreign body
reactions, and other rare causes.3,5
In general, the basic process used to
diagnose TB of the penis includes physical
examination revealing typical clinical features,
positive Mantoux test, raised ESR, and the typical
histopathological findings. More specifically, the
presence of acid-fast bacilli in the smear
examination, and typical granuloma with giant
cells and caseous foci on histopathology with no
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evidence of malignancy can help to clinch the
diagnosis. Furthermore, chest X-ray, intravenous
pyelography (IVP), urine culture and culture for
Mycobacteria should be done to differentiate
primary
from
secondary
manifestations.9
Intravenous urography should also be carried out
to exclude upper renal tract TB.2 Clinical cure is
possible through the treatment regimen described
in the preceding case study, but relapses have
been known to occur, making follow-up a
necessity. Patients diagnosed with penile TB
should be counseled to abstain from sexual
contact or at least use a condom for 4 to 6 weeks
following treatment.8
As with penile TB, the finding of
caseating granulomas and Langerhans giant cells
in association with chronic inflammation is
diagnostic of endometrial TB. Though the
tuberculin skin test does have some utility, it is
not the most sensitive test available.
Hysterosalpingograms (HSG’s) are very useful
for visualizing the internal anatomy of the uterus,
which may reveal features such as calcifications,
occlusions, ‘beaded’ Fallopian tubes (if infected),
and irregular uterine outlines if the patient does
indeed have genitourinary TB. However, even if
a female patient is correctly diagnosed and
effectively
treated
with
antitubercular
medications, the prognosis for future pregnancies
remains poor.8 Thus, it is important to prevent the
transmission of endometrial TB by all possible
routes, including sexual transmission.
Conclusions
Although TB of the penis is rare, physicians need
to be aware of this infectious disease when
undiagnosed ulcers on the penis are observed. In
particular, suspicion of cutaneous TB should be
raised in countries which still show a high
prevalence of tuberculosis, such as India where
one third of the population is infected.2 Given that
endometrial TB is associated with infertility, it
should also be considered in female patients from
TB endemic regions that have difficulty
conceiving. Since sexual transmission of TB is
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possible, as evidenced by the case reports in this
article, it is also important to consider the
implications for partners of infected patients
engaging in unprotected sex. Thus, awareness of
the extrapulmonary manifestations of TB and
proper counselling of patients with GU
manifestations in particular is crucial in
preventing the serious sexual and reproductive
consequences of this disease.
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Rabies vaccine meets the laws of supply and demand
Dinesh Bhayana (Meds 2010)
Faculty Reviewer: Dr. Haider Hasnain
Rabies is a viral neuroinvasive disease that causes encephalopathy in mammals. Vaccination is the primary
method of rabies prevention, given as both pre- and post-exposure prophylaxis. North America is currently
experiencing a heightened rabies threat due to recent problems in vaccine production. Since 2007, the
pharmaceutical industry has been struggling to meet North American demand for the rabies vaccine. The
Food and Drug Administration (FDA) and the two vaccine-producing pharmaceutical companies, SanofiPasteur and Novartis, are jointly responsible for the current supply shortage. This shortage of rabies
vaccine has resulted in a rationed approach to delivering prophylaxis. Conservative measures such as
avoidance behavior and vaccination of animals are to be used in place of pre-exposure prophylaxis. Public
health officials must review all cases in which post-exposure prophylaxis is requested to ensure the limited
supply of vaccine is appropriately distributed.
Introduction

Background and epidemiology

Rabies is a viral neuroinvasive disease that causes
encephalopathy in mammals. The most common
vector for human infection is animal bites, and if
untreated, rabies is almost always fatal. While
rabies has been well controlled or eradicated in
some areas of the world, death from rabies is not
uncommon in Asia and Africa. Prevention of
rabies by vaccination has been a mainstay of
prophylaxis since the late 19th-century and is
largely responsible for declining incidence in both
animals and humans in North America.1

Rabies is considered a zoonotic infectious
disease. This implies transmission to humans and
animals occurs via other animals. It is an RNA
virus belonging to the family Rhabdoviridae and
genus Lyssavirus and is contained in the saliva of
infected mammals.1 After a bite occurs, the virus
enters the central nervous system of the next host
and causes non-specific prodromal symptoms
followed by progressive encephalitis that is
almost always fatal. Early symptoms include
paresthesias, pruritis and pain at the site of viral
entry. In humans the incubation period usually
varies from several weeks to months. Diagnosing
rabies is difficult due to the long and variable
incubation time, as well as the lack of symptom
specificity.2

North America is currently experiencing a
heightened rabies threat due to recent problems in
vaccine production.
Since 2007, the
pharmaceutical industry has been experiencing
problems in meeting North American demand for
the rabies vaccine. This has affected the front
lines of medicine by causing a disturbance in the
practice of rabies prophylaxis.2 Here we will
discuss rabies and the rabies vaccine, the events
that precipitated the current shortage in supply
and how this production-related strain on
resources has caused a reactionary change in the
practice of medicine.
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Historically, the most common vectors for
rabies transmission have been domestic and stray
dogs and cats. In the United States in 1946 over
8300 rabies cases were reported among dogs. By
2006, aggressive canine vaccination programs and
improved stray animal control have resulted in a
greater than ten-fold reduction in canine rabies
cases. This has translated into a roughly ten-fold
drop in human rabies cases in the United States.3
There has been an increasing rate of rabies in

traditionally forest-dwelling wildlife such as
skunks, bats and raccoons. This is concerning as
urbanization and suburbanization increases in
North America and these animals are in greater
contact with humans. Between 2000 and 2005,
40% of Canada’s 2238 confirmed animal rabies
cases were skunks, 26% were bats, and 8% were
raccoons. Only two rabies deaths have been
reported in Canada since 1985 and both were
caused by bat exposure.4 Responding to changes
in the pattern of rabies transmission requires
adequate supply and effective use of preventive
measures.
The rabies vaccine and prophylaxis
Prior to the development of the first rabies
vaccine by Louis Pasteur and Emile Roux in
1885, almost all rabies infections resulted in
death. This early vaccine was developed by
harvesting cells from nerve tissue of infected
rabbits.5 Research into an attenuated strain of the
virus led to the development of new vaccines
including the human diploid cell rabies vaccine in
1967 and a newer, less expensive purified chick
embryo vaccine. These are available as Imovax®
by Sanofi-Pasteur and RabAvert® by Novartis,
respectively. They are the only two rabies
vaccines currently approved for use in Canada
and the United States.
In humans, rabies vaccines are intended
for pre- and post-exposure prophylaxis. Preexposure prophylaxis is indicated for those at
high risk of contacting the virus, such as
veterinarians, animal trappers, and travelers to
certain regions in Asia and Africa. Post-exposure
prophylaxis is given to those who have
experienced open skin wounds as a result of an
animal encounter. Individuals that have never
received the vaccine and are in need of postexposure prophylaxis also require rabies
immunoglobulin
to
provide
intermittent
immunity. Post-exposure prophylaxis with rabies
vaccine in humans has been validated as an
effective and safe method of preventing infection,
particularly when administered within 6 days of
exposure.1 Thus, the recent shortage in rabies
vaccine supply to North America has been of
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great concern, particularly to those in immediate
need of prophylactic treatment.
Cause and implications of the vaccine shortage
A current shortage of rabies vaccine has resulted
in a rationed approach to delivering prophylaxis
in North America. Much like other elements of
preventive medicine such as colonoscopies, the
indications for receiving the rabies vaccine have
become more stringent in response to strained
resources. Unique to the shortage of rabies
vaccine is that the origin of the resource
constraint is not intrinsic to the healthcare system;
there are no infrastructure, human resource or
financial constraints limiting the use of rabies
vaccine. The Food and Drug Administration
(FDA) and the two vaccine-producing
pharmaceutical companies, Sanofi-Pasteur and
Novartis, are jointly responsible for the current
supply shortage.
In June 2007, Sanofi-Pasteur began
renovating its Imovax® production facility in
France in order to comply with new requirements
from the FDA and a French regulatory body.
Prior to these renovations the company stockpiled
a finite amount of vaccine that was expected to
meet demand until the facility re-opened. Shortly
after renovations began it became evident that the
estimation of demand was incorrect and the
stockpiled supply would be inadequate.6 Also at
this time Novartis, which controls 50% of the
North American rabies vaccine market,
experienced FDA scrutiny and was asked to
temporarily halt production of RabAvert®.
Public health and industry officials have since
declared that the rabies vaccine should be used for
post-exposure prophylaxis only. Conservative
measures such as avoidance behavior and
vaccination of animals are to be used in place of
pre-exposure prophylaxis. Public health officials
must review all cases in which post-exposure
prophylaxis is requested to ensure the limited
supply of vaccine is appropriately distributed.
RabAvert® was recently cleared by the FDA, and
Novartis has been attempting to meet vaccine
demand. However, as of October 2008, the
Center for Disease Control (CDC) has not
changed recommendations for prophylaxis and
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has informed travelers to certain regions in Asia
and Africa that pre-travel vaccination is not
available.6 Current projections estimate the supply
of vaccine to restore to normal in mid-2009 upon
the re-opening of the Imovax® production
facility.6

allowing them to attain both timely and high
quality care.
While these examples are
considered to be largely intrinsic to our method of
healthcare delivery, it is important to note that
external forces may also drastically change the
practice of medicine.

Discussion

The current philosophy of medicine in the
Western World requires the efficient production
of pharmaceutical agents as well as regulatory
bodies to ensure the safety of the population. The
nature of the pharmaceutical industry makes it
necessary for the practice of medicine is agile and
prepared to deal with sudden change.

For many years the international pharmaceutical
industry has acted alone and in conjunction with
governments around the world to change the
landscape of modern medicine.
Positive
economic pressure, such as the encouragement of
research and development by government
incentives, has translated into economic growth
for nations and an intended improvement of
quality of life of the masses. Stringent regulatory
forces on the pharmaceutical industry have also
had a trickle-down effect in which government
bodies or other stressors temporarily shock the
business of drug production, which in turn
changes the way medicine is practiced. This is
evident in the recent shortage of rabies vaccine in
North America.
The practice of medicine in Canada has
attempted to demonstrate flexibility and poise
amidst a storm of stressors. Elements of
healthcare delivery have crumbled in the face of
limited resources while other areas have thrived
on the heels of innovation. For example, some
Canadians have had to seek more timely care in
the United States or overseas. However, others
have benefited from new models of primary care,

Page | 52

References
1. Manning SE et al. Human rabies prevention –
United States 2008. Morbidity and Mortality
Weekly Report (CDC) 2008; 57:1-26, 28.
2. Haider S. Rabies: Old disease, new challenges.
CMAJ 2008; 178(5): 562-563.
3. Blanton JD, Hanlon CA, Rupprecht CE. Rabies
surveillance in the United States during 2006. J Am
Vet Med Assoc 2007; 231:540--56.
4. Plotkin SA. Rabies. Clin Infect Dis 2000; 30:4-12.
5. Geison GL. Pastuer's work on rabies: Reexamining
the ethical issues diagnosis for developing
countries. Hastings Center Report 1978: 26.
6. Rabies vaccine supply situation [Internet]. Centre
for Disease Control and Prevention; 2008 October
8 [cited 2008 November 24]. Available from:
http://www.cdc.gov/rabies/news/RabVaxupdate.ht
ml.

FEATURE
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Introduction
When one thinks of infectious disease,
endocarditis – infection of the heart- does not
always leap to mind. However endocarditis is a
serious life-threatening condition if not diagnosed
and treated promptly. Infective endocarditis is
inflammation of the inner surface of the heart
following microorganism colonization. This
creates the prototypical lesion of infective
endocarditis called the vegetation, a mass of
platelets, fibrin and microorganisms. Infective
endocarditis results in damage and destruction of
heart valves, specifically the aortic valve. The
purpose of this article is to provide a synopsis for
medical students about the prevalence of infective
endocarditis, the pathogenesis and microbes
responsible for the disease and the signs and
symptoms of infective endocarditis, with
particular emphasis on diagnosis and treatment.
Epidemiology and Pathogenesis
Infective endocarditis is a relatively uncommon
infectious disease, but failure to recognize it in
predisposed patients can have disastrous
consequences resulting in heart failure, embolism
and even death. It occurs with an incidence of 1.7
to 7.0 episodes per 100 000 people in North
America, and occurs in 1.4% of patients within
the first year following
aortic valve
2,3,4,5
replacement.
Patients on dialysis infrequently
develop endocarditis, but have high mortality.
For a patient to develop endocarditis of the aortic
valve, they typically have a cardiac abnormality
leading to jet injury across the valve and they
must have blood borne microbial colonization of
the valve surface.1 Patients at particular risk for
developing infective endocarditis may have a
congenital heart abnormality, such as congenital
UWO Medical Journal, Vol 78, Issue 2

bicuspid aortic valve, degenerative aortic stenosis,
aortic calcification, rheumatic aortic valve disease
or prosthetic heart valves.
Highly virulent
microorganisms, such as Staphylococcus aureus,
can cause endocarditis in people with normal
aortic valves.
The pathogenesis of aortic valve
endocarditis occurs from a sequence of events
which allow microorganisms to gain access to the
valve and destroy it. An initial insult to the valve
occurs, independent of infection, damages the
valve and allows microbes to colonize.
Microorganism colonization may spread to the
adjacent structures such as aortic annulus, mitral
valve and aortic root and form an abscess. It is
possible for the abscess to rupture and spread into
the pericardial cavity. Infective endocarditis
destroys the cusps of the aortic valve and can also
lead to cardiac fistulas and paravalvular
abscesses. Thrombosis of microbial vegetations
from the aortic valve can lead to coronary and
systemic embolic events such as acute myocardial
infarction,
cerebral aneurysms, strokes, or
ischemic arterial occlusions.6 Organs at particular
risk of infracting from vegetative embolisms are
the spleen, the liver, the kidneys and limbs.29 The
mitral valve can become secondarily involved if
large vegetations from the aortic valve prolapse
into the left ventricle and contact the leaflets of
the mitral valve.7,8
The infective organisms involved in aortic
valve endocarditis depend on whether the valve is
native or prosthetic. Staphyloccous aureus and
streptococcus viridans are the two most common
bacteria responsible for infecting native heart
valves. S. aureus is very virulent and can cause
infective endocarditis in people with no
predisposing cardiac lesions. S. viridans is not as
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virulent and infects people with predisposing
lesions, such as calcified aortic valves or
congenital bicuspid valves.
Streptococcus
epidermidis and other streptococci are also able to
infect native heart valves.
Endocarditis due to Gram negative
bacteria is uncommon, but is very serious as these
microbes tend to be antibiotic resistant. These
microbes include Hemophilus, Actinovacillus,
Cardiobacterium, Eikenella and Kingella – the
HACEK group of bacteria. Endocarditis due to
fungal infection predominantly involves Candida
albicans and Aspergillus fumigatus and tends to
be rare but extremely serious.
Prosthetic valve endocarditis is defined as
early onset if it occurs within two months after
valve replacement and is considered late if it is
more than two months after surgery.10 Prosthetic
valve endocarditis can be due to colonization of
the valve after the surgery or due to a
contaminated valve being implanted, which may
lead to endocarditis up to one year after surgery.10
Early prosthetic valve endocarditis is due to
contamination of the valve at the time of surgery.
The microbes responsible are S. aureus, S.
epidermidis and Enterococcus faecalis.5,11 The
etiology of late prosthetic valve endocarditis is
more difficult to determine, but it is most likely
due to bacteremia and colonization of the
prosthetic valve, usually by S. aureus or, S.
epidermidis but can be caused by many other
microbes.12,13,14 It is important to obtain blood
cultures in endocarditis patients, so as the correct
antibiotic can be used, however, there are cases of
culture negative endocarditis where no
microorganism is cultured from the valve tissue
or from blood.11
Diagnosis
Clinically, endocarditis is classified as acute or
subacute. Subacute endocarditis is caused by less
virulent organisms, such as S. viridans, and
occurs in patients with a preexisting diseased or
prosthetic aortic valve. Patients present with low
grade fever, malaise and symptoms suggestive of
the flu. Physicians tend to treat these patients
with antibiotics which will improve symptoms
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within 10 days; however discontinuing the
antibiotics may cause symptoms to return. On
physical exam, the patient’s only abnormal heart
findings may be an aortic murmur. Other
physical findings include splenomegaly and
petechia, a rash caused by hemorrhage of
capillaries that can occur anywhere on the body.
Patients with long standing congenital valve
disease may also have evidence of clubbing.
Patients can present with congestive heart failure
(CHF) due to aortic insufficiency. Vegetation
thromboemoblism can also occur causing
myocardial infarction, stoke, splenic or hepatic
infarcts. Blood cultures should be obtained, as
well as complete blood cell count looking for
leukocytosis or anemia which may indicate
infection.
Acute endocarditis is generally caused by
more virulent organisms like S. aureus, and can
affect people with normal aortic valves.
Antibiotics alone will not be able to eradicate the
infection. Patients present with all the signs and
symptoms of subacute endocarditis but have more
severe symptoms and overwhelming sepsis.
Signs unique to acute endocarditis include the
Janeway lesion, a painless red-blue lesion found
on the soles of feet and the palms of the hands,
and the Roth spot, an oval pale area surrounded
by hemorrhage in the optic disc.
Acute
endocarditis patients may not necessarily have a
history of pre-existing valve disease. If the
patients have a paravalvular abscess, they likely
have abnormal EKG findings including prolonged
PR interval or evidence of heart block.
Doppler echocardiography is an extremely
useful tool in diagnosing infective endocarditis. It
is able to detect vegetations as small as 1-2 mm in
size and is very sensitive in detecting paravalvular
abscess and cardiac fistulas.
In general,
transesophgeal echocardiography (TEE) with
multiplane views is much more sensitive than
transthoracic echocardiography (TTE)14,15
Physicians
from
Duke
University
recommended criteria for the diagnosis of
infective endocarditis, which has been modified
over the years in attempts to improve its
limitations.16 In general, there are major and

minor criteria which are suggestive of
endocarditis. A patient is said to definitively have
endocarditis if they have two of the major criteria,
or 1 major criterion and 3 minor criteria, or 5
minor criteria. A patient is said to possibly have
endocarditis if they have 1 major criterion and
one minor criterion or if they have 3 minor
criteria (Table 1).
Treatment
The first line treatment of infective endocarditis is
use of antibiotics. The choice of antibiotic
depends on the clinical circumstances and should
begin after obtaining blood cultures. Patients
with recent dental work should be given
antibiotics against bacteria of the oral cavity.
Patients with a recent urinary or colonic
procedure should be given antibiotics against
Gram negative bacteria. IV drug users are at risk
of S. aureus and S. epidermidis, and antibiotic
therapy should be directed against these bugs.
The use of 2 or 3 antibiotics that will increase the
effect of each other is the best treatment for
endocarditis caused by virulent organisms, and
should be administered intravenously for 6 weeks.
It often proves difficult to treat endocarditis with
just antibiotics, especially when dealing with
virulent organisms, like S. aureus, Pseudomonas
aeruginosa, Serratia marescens or fungus

endocarditis. These organisms destroy the native
aortic valve leading to aortic insufficiency and
congestive heart failure (CHF).
Once antibiotic therapy has been started,
surveillance blood cultures should be taken within
48 hours to monitor the efficacy of the treatment.
The patient should be monitored for signs of
CHF, thromboembolism and infection. In the two
weeks following diagnosis, the patient should
have daily electrocardiogram (EKG) and frequent
echocardiogram. Abnormal findings of aortic
abscesses or large vegetative growths should
prompt immediate surgical intervention to prevent
heart failure, shock or embolism.14,17,18
Anticoagulation therapy isn’t recommended in
patients with endocarditis. It does not prevent
embolization of vegetations and it is associated
with an increased risk of neurological
complications.19
Patients with endocarditis who develop
CHF, acute valve dysfunction, paravalvular
abscess, cardiac fistula, sepsis or embolization of
vegetations despite adequate antibiotic therapy
should receive surgical intervention. Patients
with prosthetic valve endocarditis, especially
mechanical valves, who are infected with S.
aureus have better outcomes with early
surgery.9,13

Table 1 - Modified Duke criteria for diagnosis of infective endocarditis.16
Definite infective endocarditis
Pathologic criteria
(1) Microorganisms demonstrated by culture or histologic examination of a vegetation, a vegetation that has
embolized, or an intracardiac abscess specimen; or
(2) Pathologic lesions; vegetation or intracardiac abscess confirmed by histologic examination showing
active endocarditis
Clinical criteria
(1) 2 major criteria; or
(2) 1 major criterion and 3 minor criteria; or
(3) 5 minor criteria
Possible infective endocarditis
(1) 1 major criterion and 1 minor criterion; or
(2) 3 minor criteria
Rejected
(1) Firm alternate diagnosis explaining evidence of infective endocarditis; or
(2) Resolution of infective endocarditis syndrome with antibiotic therapy for 4 days; or
(3) No pathologic evidence of infective endocarditis at surgery or autopsy, with antibiotic therapy for 4 days; or
(4) Does not meet criteria for possible infective endocarditis, as above
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Patients undergoing urgent heart surgery
for endocarditis often have poor heart function
and the surgical procedure is both lengthy and
complex. In patients with infection limited to the
cusps of the aortic valve, the native valve should
be removed and replaced with a prosthesis. There
is no evidence whether mechanical or
bioprosthetic valves are superior in endocarditis
patients, and treatment will ultimately depend on
the preference of the surgeon and the patient.23 In
young patients, some surgeons prefer the use of
pulmonary autografts.24
Involvement of the aortic annulus,
whether necrosis or inflammation, needs to be
surgically resected before implanting a prosthetic
valve and patched over with autologous
pericardium or glutaraldehyde fixed bovine
pericardium.25,26 In extensive destruction of the
aortic root, all infected tissues should be resected
and replaced with a pulmonary autograft.27 The
effects of infection associated with endocarditis
are unpredictable, and as such different parts of
the heart will need to be resected, repaired or
replaced depending on the degree of damage.
Postoperatively, patients should be
observed closely.
Sepsis, coagulopathy and
hemorrhage
are
common
postoperative
complications.
Coagulopathy and bleeding
should be treated with antifibrinolytic agents,
fresh frozen plasma, platelets, and cryoprecipitate
as needed. Resection of an aortic root abscess can
lead to heart block and patients may require
implantation of pacemakers. Further surgical
treatment may be required for metastatic
abscesses and vegetative embolisms to other
organs, requiring collaboration with other surgical
specialties.

interventions are reserved for those with uncontrollable sepsis, structure-related heart failure,
abscess formation, large vegetations and
prosthetic valve endocarditis.
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Hamid Mithoowani (Meds 2012) and Nihal Haque (Meds 2012)
Faculty Reviewer: Dr. Zafar Hussein
Introduction to influenza A (H5N1)
Avian flu, or Influenza A (H5N1), is an RNA
virus belonging to Influenzavirus A, one of the
five genera classified under the Orthomyxoviridae
family. Influenzavirus A has only one species,
Influenza A, which has been responsible for all
worldwide influenza pandemics.1 These viruses
are further subdivided according to two important
surface protein antigens, hemagglutinin and
neuraminidase. Variations within these proteins
have been responsible in pandemic strains of
influenza such as the Spanish Flu (H1N1), which
claimed upwards of 20 million lives.2 Human
cases of Avian flu primarily belong to the H5N1
subtype, though rarer subtypes others have been
noted.1 The presentation and vaccine development
of the H5N1 subtype is contrasted to H1N1, but
the same applies for H3N2, the other major
subtype of human influenza virus.
H5N1 human infection was discovered in
1997 and subsequently re-emerged in 2003-2004
in poultry and human populations in several
Asian countries.1 Patients present with symptoms
2-4 days after exposure but may be asymptomatic
for up to 8 days.1, 2 Unlike seasonal influenza, the
nature of virus shedding in these cases is
unknown at this point. Besides the common
symptoms of cough, fever and shortness of
breath, there are several features unique to
infection with H5N1. Unilateral pneumonia
progressing into a bilateral pattern within the span
of 4 days is more common and can be detected on
an X-ray. This is different from the cases of
pneumonia which develop subsequent to H1N1
infection as they are quite rare. The mortality of
patients infected with H5N1 approaches 60% and
death occurs due to respiratory failure secondary
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to fulminant bilateral pneumonia.2 It should be
noted that this rate has been obtained from
reported cases and that the actual number might
be higher. As opposed to H1N1, H5N1 might
involve extrapulmonary sites as well. For
example, viral RNA has been isolated from the
blood of patients who died from H5N1 infection.3
Furthermore, viral RNA has also been detected in
areas such as the liver, lymph nodes and brain.4
This may explain why H5N1 infection also
produces gastrointestinal symptoms such as
diarrhea, vomiting and abdominal pain.
In the event of an outbreak of H5N1
infection, the modes of transmission of the virus
must be examined in order to initiate effective
countermeasures. The H5N1 virus is present in
poultry and most cases of human infection have
occurred in situations where there is close contact
with live or dead birds.3 There is also the
possibility that infection occurs via the
gastrointestinal tract as viral RNA has been found
in feces of infected individuals.6 Finally, there
have been very few cases of human-to-human
spread at present and these cases involved lengthy
contact with infected individuals.7 In summary,
both animal-to-human and human-to-human
spread remains inefficient at present but this
could change if a mutation occurs in the H5N1
virus.
Vaccine development
The World Health Organization monitors
influenza activity throughout the world and makes
a recommendation for the seasonal influenza
vaccine every year.8 Postinfection ferret sera are
tested in an assay called the hemagluttinationinhibition (HI) test where hemagluttinin from

different strains of H1N1 are tested to see which
elicits the highest immune response. This data is
used to make a recommendation around February
for the upcoming influenza season.
An ideal vaccine for H5N1 infection
should induce a strong mucosal antibody (IgA)
response as the primary site of H5N1 infection is
the respiratory tract.9 Due to the extrapulmonary
nature of H5N1 infection, a vaccine which
induces a cell-mediated response as well would
help protect from systemic manifestations of
infection. This cell-mediated response needs to be
generated against conserved elements of the virus
such as matrix and nucleoproteins as other
components mutate rapidly. Finally, this vaccine
should be easy to produce as large amounts will
be needed in the event of a potential or imminent
pandemic.
Inactivated H1N1 influenza viruses are
used for prophylaxis against seasonal influenza.9
This approach is restricted to a humoral immune
response only. Live attenuated H1N1 viruses
were developed to overcome this hurdle as they
induce cell-mediated responses as well. These
approaches are not helpful for H5N1 human
infection because of the long period of time
required to produce these vaccines due to the
requirement of chicken eggs to complete the
process. Another problem with using live
attenuated viruses for H5N1 infection prophylaxis
is that there is the chance of developing a deadlier
strain if they undergo genetic reassortment with
another strain. Live attenuated H5N1 viruses have
been shown to induce immunity in chickens when
challenged to H5N1 infection however and will
most likely be used as a last resort during a
pandemic. 10
The use of adenoviruses as vectors
provides an attractive alternative to develop
vaccines for H5N1 human infection.11
Specifically, adenovirus serotype 5 can be
genetically engineered to express hemagluttinin
specific to H5N1. The production of adenovirus
vectors is faster than that used for influenza
vaccines since they do not require the use of
chicken eggs. These vaccines can be administered
intranasally and this eliminates the need for
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specialized personnel to administer them in the
event of a pandemic. The main drawback to this
modality is that a certain segment of the world
population is immune to this subtype of
adenovirus and this may dampen the response to
hemagluttinin required as the virus may be
cleared quickly. However, it has been shown that
even in people who possess natural immunity, the
vaccine induces antibody production against
hemagluttinin.11 Once large-scale studies
examining the safety profile and efficacy of
adenovirus-vectored vaccines is complete, they
can be produced in large quantities to be used as
prophylaxis during a pandemic.
The role of influenza A (H5N1) vaccines in a
global pandemic
A potential H5N1 pandemic can be a serious
threat to global health. Applying data from the
1918 flu pandemic, a computer model has been
developed that predicts between 50 and 80
million people worldwide could be victims to
Preventing a pandemic of this
H5N1.12
magnitude requires controlling it and containing it
as early as possible. Vaccines play an important
role in controlling H5N1, and the World Health
Organization (WHO) has announced that they
will be stockpiling vaccine in preparation for a
global pandemic.13 The current plan put forth by
the WHO is to stockpile 50 million vaccines,
which would protect 25 million people at two
doses per person.14 The WHO is charting new
territories with regards to stockpiling vaccines.
Usually, vaccines for pandemics cannot be
prepared until the particular strain of virus makes
its way into the population. Using current vaccine
development technology, this could take at least
4-6 months after the WHO declares a particular
strain of virus to be a pandemic.15 The current
strategy is to stockpile “prepandemic” vaccines.
This involves preparing vaccines with currently
circulating H5N1 strains, but with cross-reactivity
to other emerging strains. For the development of
an effective vaccine, it is essential to monitor
H5N1 strains as well as any drift which occurs by
the accumulation of mutations in H and N
antigens. This would require rapid testing of
patients at the level of individual communities.
Cultures should be obtained from patients in
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designated clinics which are representative of the
community.16 This information should then be
escalated to a local public health office. Patients
receiving the vaccine would be primed towards
H5N1, buying time until a more specific booster
is developed and administered.17 To adapt to other
strains, cross-reactivity is elicited by adding
certain adjuvants to the vaccine, which also
induce a stronger immune response and require
lower doses of vaccine to be administered.
GlaxoSmithKline is developing an inactivated,
prepandemic vaccine for H5N1 which has
undergone phase I and II clinical trials, and has
been found to be safe in healthy adult
volunteers.18
There are logistical issues surrounding
stockpiling not limited to distributing of millions
of vaccines and making vaccines available to the
developing world. It is a global responsibility to
ensure that the developing world receive vaccines
and will require global cooperation. The WHO
has not come up with a specific plan regarding the
stockpile use, and admit to still working on one.
Another issue is the lack of data regarding
vaccine safety and efficacy in large human
clinical trials. There is little research on the
vaccine in paediatric and elderly populations,
which are considered to be at the highest risk for
H5N1. Careful thought and planning must go into
making decisions not only at the level of the
laboratory, but in policy to ensure that stockpiling
vaccines can be taken seriously as a solution to
prevent a worldwide H5N1 pandemic.
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FEATURE
Respiratory infections in the homeless
Olga Wrezel (Meds 2009)
Faculty Reviewer: Dr. Jamie Harris
Many people are affected by homelessness worldwide, in Canada and the U.S. Homelessness is associated
with an increased risk of health problems due to overcrowding in shelters and host factors such as substance
abuse, HIV co-infection, poor nutrition and hygiene, mental illness and trauma. Respiratory infections are
among the most common problems that the homeless may present with and are associated with high
morbidity and mortality. Certain respiratory infections are more common among homeless individuals and
may be associated with complications unique to this population. Most of the literature in the field focuses
on tuberculosis in the homeless or on specific outbreaks of respiratory infections. This article discusses the
prevalence, risk factors, complications, treatment and prevention of tuberculous and non-tuberculous
respiratory infections such as influenza and pneumonia caused by S pneumoniae, S aureus, H influenzae b,
and anaerobes.
Introduction
Homelessness is an alarming social problem that
affects up to 100 million people worldwide.1 The
2001 Canadian census counted 14,145 individuals
living in shelters, however, this largely
underestimates the number as many homeless
may not stay in shelters.2 Homelessness is also a
significant health problem. Crowded shelters are
favorable environments for infection and host
factors such as poor nutrition, obesity, sedentary
lifestyle, poor hygiene, alcoholism, drug use,
smoking, mental illness, abuse, trauma, or HIV
co-infection increase susceptibility to illness and
may diminish immune systems.3,4,5,6 These
factors, combined with decreased financial and
personal resources, make the seeking out of
medical help and compliance with treatment less
likely. As a result, homeless people are more
likely to suffer from respiratory infections, skin
and foot infections, hepatitis, HIV, STI’s, and
chronic disease.5
Respiratory infections are among the most
common medical issue that homeless individuals
seek help for and shelters can be sources of
outbreaks of tuberculosis and pneumonia.7
Respiratory infections account for 33-42% of
presenting complaints and 20% of total deaths in
UWO Medical Journal, Vol 78, Issue 2

the homeless.3,8,9 The mortality due to respiratory
illness is about seven times greater than expected
in the homeless.9,10 This is compounded by the
increased rate of chronic respiratory illness such
as bronchitis (11.4%), asthma (8.6%) and COPD
(5%). Several factors specifically predispose this
population to respiratory infections including
crowding, increased exposure to pathogens,
smoking, alcohol and drug abuse, HIV
seropositivity and chronic lung disease.3,6,9 This
article will examine both tuberculous and nontuberculous respiratory infections such as
pneumonia and influenza in the homeless as they
are not only more common but are associated
with
greater
morbidity,
mortality
and
complications.
Tuberculosis
Tuberculosis is the most common respiratory
infection among the homeless that is discussed in
the literature. The estimated annual pulmonary
TB rate for Canada and the U.S. is 2 per
100,000.11 The urban homeless comprise a
disproportionate burden of tuberculosis. The
prevalence of active tuberculosis among the
homeless in the U.S. is 1.6% to 6.8% and 18% to
51% for latent disease.8
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As with other respiratory infections,
poverty, malnutrition and overcrowding are all
risk factors for tuberculosis. Larger, more
crowded shelters with increased people sharing
the same breathing space increases transmission
and poor ventilation or recirculation of air
compounds this risk.8 HIV co-infection and
alcoholism commonly complicate the course of
infection. HIV is the single-most important risk
factor for latent disease progressing to active
disease and it is recommended that all individuals
with TB be tested for HIV.5,8 Some studies link
multi-drug resistance to homelessness, although
contradictory data disputes this.5,12 Homelessness
is associated with poor adherence, loss to followup and is an independent risk factor for no
contacts.12,13 Contact tracing is accomplished by
mass screening in shelters as opposed to
searching for named contacts.3

chest radiography, TST and sputum culture upon
shelter admission before access to free meal
services.17
Lack of treatment compliance is a
common problem among the homeless. A 48%
non-compliance rate was reported in New York in
1991 leading to increased length of treatment
(560 versus 324 days) and decreased completion
of treatment. Directly observed therapy (DOT)
and supervised housing programs are both
effective
methods
used
to
increase
5,8,18
compliance.
Other novel solutions include
financial or food incentives, transportation
assistance and education using a peer health
advisor.5,8,19 More dramatically, incarceration has
also been evaluated as a method for treating
patients refusing treatment.8,20
Pneumonia

Screening and detection in the homeless is
important for preventing TB resurgence.14 The
CDC recommends that the detection of
tuberculosis be given first priority as opposed to
screening asymptomatic individuals.8 City-wide
symptom screening programs have been
implemented in Philadelphia shelters on intake to
ensure that symptoms such as prolonged cough,
night sweats, fever, and weight loss are further
investigated.15 Mass screening in shelters has also
been widely used with resulting decreases in
tuberculosis transmission. No consensus has been
reached about the most effective screening tool.1
Tuberculin skin testing (TST) is likely the
simplest and least expensive to administer, but
lacks specificity and results in many false
negatives in the immunocompromised.1,16
Mandatory skin test screening in one U.S. study
resulted in a decreased incidence of TB from 510
to 121 cases per 100,000 per year.1 Spot sputum
is also a fairly rapid screening technique but 50%
of smears are negative and subsequent tracing of
patients is difficult.1,8 Studies in incarcerated
individuals show that chest radiography is likely
to be the most cost-effective method. Annual
snapshot screening for tuberculosis in shelters
using combinations of these methods has been
undertaken in Los Angeles and Marseille with
great effectiveness.1 Certain shelters, as in
Barcelona, imposed mandatory screening with
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Pneumonia affects over 1 million Americans
annually and is the 6th leading cause of death with
a 14% mortality rate among hospitalized
patients.21 This burden is disproportionally shared
by the homeless. An Edmonton-based study from
2000-2002 showed a pneumococcal infection rate
among the homeless of 266.7 per 100,000
contrasted with 9.7 per 100,000 in the general
population.
Outbreaks
of
pneumococcal
pneumonia more commonly occur in crowded
shelters with high pneumococcal carriage rates of
up to 60%. Shelter outbreaks in Chicago, Boston,
Paris and the UK as well as in several provinces
of Western Canada have been described in the
literature. 20,22
In addition to homelessness, risk factors
for pneumonia include smoking, drug or alcohol
use, HIV, asthma and COPD; all frequent
comorbidities in the homeless. It is estimated that
78% of homeless individuals are smokers and
60% abuse alcohol.3,9,22,23 In two shelter
outbreaks in Boston and Paris, the majority of
those infected were alcoholics, smokers or had
chronic bronchitis.9,24 Outbreaks of Hib
pneumonia are also mostly found among
alcoholic homeless patients.3,9

The most common organisms responsible
for community acquired pneumonia in the
homeless are Streptococcus pneumoniae,
Staphylococcus aureus, and H influenzae b.
Aspiration pneumonia is also frequent and
organisms
include
anaerobes
like
peptostreptococcus, Fusobacterium nucleatum,
Prevotella and bacteroides species. Pneumocystis
carinii can be found in HIV positive
individuals.20,21,22
Vaccination
against
pneumococcal
pneumonia is one method of reducing invasive
pneumococcal disease in shelters.25 The Canadian
National Advisory Committee on Immunization
(NACI) recommends the use of 23-valent
pneumococcal polysaccharide vaccine (PPV-23)
in the homeless, those who use illicit drugs, HIV
infected individuals and those with other chronic
conditions
such
as
COPD
that
are
disproportionately higher in the homeless.
Vaccination of hard to reach populations like the
homeless can be challenging and a 1999
vaccination campaign in Edmonton addressed this
issue by targeting as many sites as possible
including single room occupancy hotels, soup
kitchens, community agencies, needle exchanges,
pubs, parks and alleys. The year following the
campaign, there was a decrease in the amount of
emergency department visits for pneumonia (863
compared to 646), and a decrease in admissions
for pneumonia.22 Vaccination is also the best way
to prevent Hib pneumonia in at-risk persons who
are not immune.23
Special considerations for pneumonia in
the homeless include keeping a high index of
suspicion for aspiration in those who abuse drugs
and alcohol. One must also consider the difficulty
of completing antibiotic regimens especially those
with frequent dosing. Furthermore, there is often
no safe storage for medications or a place to
convalesce with closures of shelters during the
day. Hospitalization or admission in a medical
respite unit is worthwhile to ensure proper
treatment.21 Smoking cessation is another
important arm of prevention although it is often
overlooked in the homeless due to falsely
assumed lack of motivation.6
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Influenza
Influenza affects millions of Americans per year
and results in 100,000 hospitalizations and 36,000
deaths annually. Influenza can result in secondary
pneumonia and exacerbations of COPD or
asthma.26 Despite the large morbidity and
mortality associated with the virus, influenza
among the homeless is very poorly studied. A
New York-based study of 3 shelters evaluated
4,319 charts for influenza-like illness with 59
recorded cases, less than one fourth of which had
been vaccinated. Vaccination against influenza
has been advocated for in those at increased risk
of influenza and pneumonia including the
homeless, HIV-infected and those with COPD.27
Influenza vaccination remains underutilized and
organized efforts concentrated over a day or week
to vaccinate all shelter residents and staff is
suggested.26 Various strategies for improving
vaccination rates include educational campaigns,
improving
patient-provider
interactions,
broadening the provider base, adoption of
standing orders for immunization administration,
and promoting wider availability and access to
vaccine at the structural level.28
Conclusion
Homeless individuals are at increased risk of
respiratory infections such as tuberculosis,
influenza and pneumonia due to S pneumoniae, S
aureus, H influenzae b and anaerobes. Risk
factors include overcrowding, increased pathogen
exposure and host factors such as alcoholism,
smoking, drug abuse, HIV co-infection and
chronic lung disease. Morbidity, mortality and
complications are greater in these specific
populations and outbreaks are common.
Diagnosis and treatment non-compliance are
serious challenges. It is important to remember
that respiratory infections and their complications
in the homeless are largely influenced by social
factors. Mindfulness of the unique risks and
challenges associated with this population is
important. It is only through comprehensive
programs that involve initiatives like screening,
immunization, low threshold for hospitalization,
smoking cessation, and incentives or education to
increase compliance, that effective prevention and
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treatment of respiratory infections in the homeless
can be attained.

14.
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CASE REPORT
A case of a middleaged man with a neck mass
Dawid Martyniak (Meds 2010)
Faculty Reviewer: Dr. William Wall
The differential diagnosis of a neck mass can be extensive. In this short publication we will focus on an
unusual neck mass whose features suggested that of extrapulmonary tuberculosis (TB). Though TB is
endemic is some developing parts of the world, its rates of infection have drastically decreased in
developed countries and the prevalence has remained relatively low. However with the emergence of AIDS
and multi-drug resistant tuberculosis, we have seen a resurgence of TB infections. Though pulmonary TB is
by far the most common presentation of tuberculosis, several extrapulmonary manifestations can present
clinically. The presentation of interest that will be discussed in this article is Scrofula – the involvement of
TB in the lymphatic system of the neck.
A 45-year-old man of Indian ethnicity presented
to the General Surgery Outpatient Clinic
complaining of a left-sided, palpable, non-tender
mass above the clavicle. The swelling had
developed over a period of several weeks and had
been progressively increasing in size. He was
concerned about malignancy. There was no
history of recent viral infections, fever, chills,
weight loss, sweats, or any other systemic
symptoms. He was otherwise healthy, active and
worked at a marketing firm. The patient's past
medical and surgical history was unremarkable.
He lived alone in an apartment and had no pets.
Two years previously he visited India for one
week. The patient did not appear sick and was in
no discomfort. His oral temperature was 36.7oC,
pulse 70bpm with a blood pressure of
140/70mmHg. A left-sided slightly indurated,
non-tender 5cm supraclavicular mass was present
just lateral to the sternocleidomastoid muscle. The
overlying skin was slightly erythematous but
there was minimal tenderness. The oral cavity,
face and scalp were normal. There was no
enlargement of axillary or inguinal nodes and no
hepatosplenomegaly.
The white blood cell (WBC) count was
normal and the erythrocyte sedimentation rate
(ESR) and C-reactive protein were mildly
elevated. An urgent contrast-enhanced computed
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tomography (CT) scan of the neck and chest
showed a 2.8 cm x 5.3 cm well delineated soft
tissue mass with a central area of lower
attenuation. It was interpreted as a necrotic lymph
node and lymphoma, metastatic cancer and
infection were listed in the differential diagnosis.
There was no mediastinal adenopathy and no
pulmonary nodules. Four days after the initial
consultation the mass was larger and fluctuant.
Using local anaesthesia it was incised and thick
pus without any odour was drained. Gram stain of
the pus showed no organisms and routine
anaerobic and aerobic cultures were negative.
Stain for Acid Fast bacilli was negative and the
culture for TB are still pending. When seen three
weeks after the drainage, mass had resolved and
the site of the incision was almost closed.
Because of the patients presentation with a
“cold abscess” (lack of locally marked findings of
redness and tenderness and absence of systemic
findings of inflammation), scrofula was
entertained in the initial differential diagnosis.
Scrofula is the term for tuberculous cervical
lymphadenitis. Its origin is the latin word
meaning “brood sow”. Scrofula has been known
to afflict people since antiquity. In the middle
ages it was believed that the royal touch of the
king could cure the disease, hence it was known
as the King's Evil. Kings were thought to have

received this power due to their descent from
Edward the Confessor. Elaborate healing rituals
were performed by monarchs to heal the afflicted
of this disease. In 1768, the Englishman John
Morley produced a handbook "Essay on the
nature and cure of scrophulous disorders” which
first described the typical symptoms and
prognostic factors.1 Epidemiologically, 95% of
the scrofula cases in adults, and 8% of cases in
children, are caused by Mycobacterium
tuberculosis. The rest are caused by atypical
mycobacterium
or
nontuberculous
mycobacterium (NTM). With the vast decrease of
tuberculosis in the second half of the 20th
century, scrofula became a very rare disease,
however with the appearance AIDS it has shown
a resurgence, and presently affects about 5% of
severely immunocompromised patients. TB is
responsible for up to 43 percent of all of
peripheral lymphadenopathy in the developing
world. Tuberculous lymphadenitis occurs in more
than 4 children per 1000.2
The most usual signs and symptoms are
the appearance of a chronic, painless mass in the
neck, which is persistent and progressive. The
mass is referred to as a "cold abscess", because
there are minimal findings of acute inflammation
accompanying local and the overlying skin
acquires a violaceous color. Scrofula caused by
Mycobacterium
tuberculosis
is
usually
accompanied by other symptoms of the disease,
such as fever, chills, malaise and weight loss in
about 43% of the patients. As the lesion
progresses, skin becomes adherent to the mass
and it may rupture spontaneously, forming a sinus
and an open wound.3
The diagnosis of scrofula definitively is
made by histology and culture of lymph node
material. Other supportive tests that may be useful
to raise suspicion include a positive PPD skin test
and chest radiography indicating pleural
thickening and apical fibrosis suggestive of
previous TB.4 Fine needle aspirate (FNA) in
seronegative HIV patients using conventional
cytology, microscopy and culture has lead to
inconsistent results,5 but one study report a
sensitivity of 77 percent and specificity of 93%.6
It is generally accepted that FNA is more valuable
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in HIV-infected patients.7 With new polymerase
chain reaction (PCR) techniques some studies
have found FNA to be almost equally sensitive to
a lymph node biopsy.8 Ziehl-Neelsen staining of
FNAs was positive in 87 percent patients with a
final diagnosis of TB according to one study.9
Excisional node biopsy can be performed if FNA
and PCR are negative. A finding of caseating
granulomas on histopathology is highly
suggestive of TB.10 Finally TB can also be elusive
to culture taking up to 4-6 weeks but sensitivity
testing can perform on the isolated organisms.11
In the patient described here, cultures for TB are
still pending to confirm the diagnosis as
mentioned earlier.
The mainstay of treatment for Scrofula has
shifted from excisional biopsy to antitubercular
agents. Treatment should be initiated before
confirmative cultures return from the lab. The
optimal duration has been found to be six months
with multi-drug therapy including isoniazid,
rifampin and pyrazinamide.12 Often patients
return early after initiation of treatment because
of a paradoxical increase in the lymph node size
due to an immune response to the mycobacteria.13
Response to therapy is excellent with relapse rates
reported at 3.5%.14
His preliminary microbiology results were
negative for acid-fast bacilli and cultures up to
one month did not show any organisms, however
TB can be difficult to culture and the lab keeps
cultures up to eight weeks to be certain.
Resolution of the inflammatory mass after
drainage would be expected, but a persistent
draining sinus would be expected if TB is the
underlying organism. Our suspicion of scrofula
remains probable given the classical clinical
presentation, negative cultures for typical aerobic
and anaerobic bacterium, and negative chest Xray for active pulmonary disease.
Due to international travel and the
prevalence of TB worldwide scrofula is important
to investigate especially due to the high mortality
of disseminated TB and curative potential
antitubercular medications. HIV positive patients
and travellers to regions with high prevalence of
TB should raise the suspicion of scrofula since
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these groups are at higher risk.15 Therefore, as
long as TB is around Scrofula should remain on
the differential for unexplained neck masses.
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RESEARCH
Antibiotic resistance knowledge in the elderly
Adeel Mahmood (Meds 2009), Raza Naqvi (Meds 2009), and Aman Grewal (Meds 2009)
Study Investigators: Dr. Laura Diachun and Dr. Iris Gutmanis
Antibiotic resistance (ABR) is a growing health care problem. Literature suggests a lack of awareness may
lead patients to pressure physicians towards inappropriate prescribing practices. Very little is known about
what seniors know about ABR. This pilot study investigated knowledge of antibiotic use, expectations
regarding the prescription of antibiotics and awareness of ABR in a community dwelling elderly
population. Thirty-eight subjects (age ≥65) were interviewed at a London senior’s centre using a structured
survey tool that explored knowledge and expectations about antibiotic use. Results reveal that 66% of
respondents were familiar with the term ‘antibiotic resistance’ and that 90% felt it was an important health
care issue. Fifty-six percent of respondents obtained this information through media-related sources, and
only 17% through their family physician (FP). However, the majority of respondents (90%) felt that it was
the role of the FP to inform the general public about the issue. Regarding patient knowledge, 26% of
respondents believed that antibiotics would help them recover from a common cold and 50% expected to
receive antibiotics if they visited their FP for a cold. Of those patients who had recently been prescribed
antibiotics, only 50% completed their prescribed course. These results illustrate the lack of knowledge held
by elders regarding appropriate use of antibiotics and a significant discord between their expectations of
their FP and the role FPs might play in educating patients about proper antibiotic use. Study methods and
the survey tool should be validated in larger future studies.
Introduction
ABR is an important healthcare issue that has
significant implications for both the individual
patient and for society as a whole.1-5 Several
studies have shown that knowledge of ABR is
lacking in some of the more educated segments of
the North American population; however,
literature regarding the knowledge of ABR among
the elderly population, a group which uses a
disproportionately large amount of antibiotics, is
limited. Further, many physicians lack knowledge
of proper prescribing practices.6-7 Improper
antibiotic prescribing practices may lead to their
unnecessary use and subsequently may contribute
to the proliferation of resistant bacteria. Thus,
correcting these practices could lead to a slowed
increase in antibiotic resistance.
The lack of patient knowledge regarding
proper antibiotic usage has been shown in several
studies to directly influence patient expectations
UWO Medical Journal, Vol 78, Issue 2

from their physician encounters.8-9 Lack of
education among patients often leads to pressure
on physicians to prescribe inappropriately.
Research has shown that physicians are especially
likely to comply with such requests from elderly
patients within their practice.10-13 One recent
study found that 46% of general internists in a US
hospital believed that patient expectations was
one of the most important causes of antibiotic
resistance.7
Another significant cause of ABR is
widespread misunderstanding regarding the
importance of completing prescribed courses of
antibiotics.10,14 This knowledge is particularly
lacking among older adults, as is health care
knowledge in general.15 Studies have shown that
increased knowledge about medications leads to
significant improvement in adherence and
compliance with treatment regimens. This
emphasizes the importance of assessing the
knowledge of elderly patients regarding ABR and
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educating this patient population about the
importance of adhering to a prescribed antibiotic
regime.9
With the current lack of information on
the knowledge of ABR and patterns of antibiotic
use among the elderly, we designed a pilot study
to better understand this important healthcare
issue, specifically targeting a sample of
community dwelling elders in London, Ontario.
We sought to understand patient expectations of
their physicians regarding the prescription of
antibiotics, patient attitudes towards antibiotics,
antibiotic usage patterns, and patient knowledge
and understanding of the concept of ABR.
Methods
A standardized survey tool was administered
through personal interviews by the student
investigators at a local community centre over a
period of three days in March-April
2007. Subjects were excluded if they were less
than 65 years of age or residing in a long-term
care or retirement home. A community dwelling
population was targeted under the premise that
they would have more control over their
medication usage patterns than those living in
more institutional settings.
Participants were not solicited. Rather,
study participants voluntarily approached the
student investigator’s table located in the lobby of
the community centre. After obtaining consent,
individual interviews were conducted by the
student investigators. No personal identifiers
were collected and no remuneration was
provided. At the completion of the interview, a
Letter of Information and a Health Canada
information sheet regarding ABR were provided
to each study participant to further their

knowledge of this issue.
Approval for this study was obtained from
the Office of Research Ethics at The University of
Western Ontario.
Results
Thirty-eight elders with a mean age of 77 years
(range: 65-92 years) were interviewed. Sixtyeight percent were female, 100% had been
employed at some time in their lives, and 97%
reported currently having a FP (mean duration of
professional relationship: 14.4 years).
Regarding elders' expectations of their
physicians, 24% indicated they would visit a
physician for common cold symptoms such as
cough, runny nose and a fever. Among those who
would visit their FP for a cold, 56% expected an
antibiotic prescription for their cold. Forty-seven
percent of subjects believed that doctors usually
prescribed antibiotics if patients felt they were
needed.
Regarding participant attitude toward
antibiotic use, 87% of respondents felt they
should not take antibiotics to prevent them from
getting a more serious illness when they had a
cold, whereas 26.3% believed that antibiotics
would help them to "get better more quickly"
from
a
cold. Half
of
all
elders
interviewed believed that if they were sick
enough to visit a physician, they would expect an
antibiotic prescription (Table 1). Of those
interviewed, 16% had used antibiotics within the
last 4 weeks, with only 50% completing the
course of antibiotics they had been prescribed.
Sixty-six percent of respondents were
familiar with the term 'antibiotic resistance'. After

Table 1: Attitudes towards antibiotic use among community-dwelling elders
% Agree
% Disagree
Item
When I get a cold, I should take antibiotics to prevent
10.5% (4)
86.9% (33)
from getting a more serious illness.
When I get a cold, antibiotics help me to get better
26.3% (10)
63.2% (24)
more quickly.
By the time I’m sick enough to visit GP from cold, I
50.0% (19)
47.4% (18)
expect an antibiotic.
Note: the number in the parentheses is the number of study respondents with this response.
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% Unsure
2.6% (1)
10.5% (4)
2.6% (1)

being read a paragraph that described ABR, 92%
felt this to be an important healthcare issue. When
asked who should inform consumers about the
issue of ABR, 90% of respondents felt it should
be physicians, 55% stated pharmacists and 29%
thought the media should educate the public. Of
those patients who had heard or read about ABR,
most indicated that they received this information
through public media (58%), 17% had received
this information through physicians and 8%
through their pharmacists. Surprisingly, 84%
indicated that their FP had never discussed the
issue of ABR, and 97% had never received
written information about antibiotic resistance
from their FP (Table 2).
Discussion
ABR is a growing health care concern. Recent
initiatives by Health Canada strive toward
educating the public about appropriate antibiotic
use and preventing unnecessary antibiotic use.
This pilot study set out to investigate the

awareness and knowledge surrounding these
elders. The majority (92%) of the respondents
considered ABR a very important healthcare
issue. However, there was large discrepancy
between patient expectations and the information
about antibiotic use provided by their healthcare
professionals.
Almost 90% of respondents felt that FPs
should be responsible for informing patients,
whereas only 17% of the respondents had actually
heard about the issue from their FP. Surprisingly,
it was media sources that had exposed most of the
respondents to the issue. This is an important
finding as the nature of the patient-physician
relationship makes it one of the primary vehicles
for reducing the number of unnecessary antibiotic
prescriptions. Most patients have a strong trust in
their physicians and educating elders regarding
proper antibiotic use may promote better health
outcomes for the patient and slow the increase of
antibiotic resistance.

Table 2: Knowledge of antibiotic resistance among community-dwelling elders
Question
% Agree
% Disagree
(a)
Are you familiar with the term ‘Antibiotic
65.8% (25)
34.2% (13)
Resistance’?
Do you think this is an important healthcare issue?
92.1% (35)
2.6% (1)
Have you ever heard or read about Antibiotic
63.2% (24)
36.8% (14)
Resistance?
Has your Family Physician (FP) ever talked to you
15.8% (6)
84.2% (32)
about Antibiotic Resistance?
Has your FP ever given your reading materials about
2.6% (1)
97.4% (37)
Antibiotic Resistance?
Does your pharmacist talk to you about your
84.2% (32)
15.8% (6)
prescription medications?
Note: the number in the parentheses is the number of study respondents with this response.

% Unsure
0%
5.3% (2)
0%
0%
0%
0%

Response
Doctor:
89.5% (34)
Pharmacist:
55.3% (21)
Media:
29.0% (11)
Other:
5.3% (2)
Among those who had heard or read about antibiotic resistance (n=24):
Media:
58.4% (14)
Where did you get this information?
Doctor:
16.7% (4)
Family/Friend:
16.7% (4)
Pharmacist:
8.3% (2)
Other:
8.3% (2)
Nurse:
4.2% (1)
Note: the number in the parentheses is the number of study respondents with this response; percentages do not
total 100% as participants could select more than one option.
Question
(b)
Who should tell people about antibiotic resistance?
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Although a majority of subjects stated that
they were familiar with the term ‘antibiotic
resistance’, our data indicate that this awareness
did not necessarily equate to evidence-based
antibiotic use. Twenty-four percent of
respondents went to their doctor for cold
symptoms and half of these patients expected a
prescription for antibiotics.
While 87% of
respondents did not believe that antibiotics could
prevent a cold, 37% believed that they could get
better faster using antibiotics. These results
suggest that even though a large number of
subjects were familiar with the term ‘antibiotic
resistance’, this did not translate to an
understanding regarding appropriate use of
antibiotics or knowledge of appropriate antibiotic
use. This is thought provoking considering that
the majority of subjects heard about ABR from
media sources. Whether education of patients by
physicians would lead to improved knowledge
and behaviors around the use of antibiotics needs
further evaluation.
While this small pilot study raised some
interesting points, further research on the topic
will be needed to support these initial
observations. As with all studies, there are
several limitations. Both the small sample size
and use of a population attending a community
centre make it difficult to generalize these
findings to all community dwelling elders. A
population regularly attending a community
centre may differ significantly from a more
sedentary population with respect to knowledge,
attitudes, self-advocacy and health behaviors.
Further, although the study questionnaire has face
validity, further evaluation of the tool is needed.
This study suggests that lack of patient
knowledge regarding contributors to the
development of ABR, as well as patient
expectations of physicians and the prescribing
practices of physicians could all be targeted in an
attempt to reduce the incidence of ABR. Further
research is required to better understand this issue
and to evaluate the efficacy of potential strategies
in reducing the development of ABR.
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